1 Supplementary Material

2 **Detailed cohort description**

3 <u>EPIC-IT</u>

The European Prospective Investigation into Cancer and Nutrition (EPIC) is a large European 4 5 study on diet and cancer and has been previously described elsewhere (Riboli 2001, Palli et al. 6 2003). The Italian component of EPIC (EPIC-IT) recruited 47,749 adult volunteers (men and 7 women) at five centres: Varese and Turin in northern Italy, Florence in central Italy and Naples 8 and Ragusa in southern Italy. All participants signed an informed consent form and completed 9 two questionnaires: one about dietary habit (food-frequency) and one about lifestyle, with information on education, socioeconomic status, occupation, history of previous illnesses and 10 surgery, lifetime tobacco use and alcohol consumption and physical activity. EPIC-IT database 11 records were linked to cancer and regional mortality registries after database quality control. 12 All EPIC-IT centres except Naples are covered by population-based cancer registries. In 13 14 Naples, follow-up information was collected from electronic hospital discharge records and also by periodic personal contact with participants. The study was approved by the ethical 15 review boards of the International Agency for Research on Cancer, and of the collaborating 16 17 institutions responsible for subject recruitment in each of the EPIC recruitment centres. All centres for EPIC Italy, except for Florence are represented in LIFEPATH. 18

Education level was collected at baseline via questionnaire as none, primary school, lower
secondary school, vocational school, higher secondary school, BSc, and MSc.

Paternal profession during childhood was collected at baseline via questionnaire as farmer, retailer, not employed, clerical worker, professional and manager, unskilled worker, skilled worker. This was categorized into manual and non-manual profession to characterize paternal occupational position.

DNA methylation measurements and pre-processing. DNA from blood samples were extracted 25 26 from buffy coats using the QIAsymphony DNA Midi Kit (Qiagen, Crawley, UK). Bisulphite conversion of 500 ng of each sample was performed using the EZ-96 DNA Methylation-Gold[™] 27 Kit according to the manufacturer's protocol (Zymo Research, Orange, CA). Then, bisulfite-28 converted DNA was used for hybridization on the Infinium HumanMethylation 450 BeadChip, 29 following the Illumina Infinium HD Methylation protocol. Briefly, a whole genome 30 amplification step was followed by enzymatic end-point fragmentation and hybridization to 31 HumanMethylation 450 BeadChips at 48°C for 17 h, followed by single nucleotide extension. 32 The incorporated nucleotides were labeled with biotin (ddCTP and ddGTP) and 2,4-33 34 dinitrophenol (DNP) (ddATP and ddTTP). After the extension step and staining, the BeadChip 35 was washed and scanned using the Illumina HiScan SQ scanner. The intensities of the images were extracted using the GenomeStudio (v.2011.1) Methylation module (1.9.0) software, which 36 37 normalizes within-sample data using different internal controls that are present on the HumanMethylation 450 BeadChip and internal background probes. The methylation score for 38 each CpG was represented as a β-value according to the fluorescent intensity ratio representing 39 any value between 0 (unmethylated) and 1 (completely methylated). 40

We extracted raw fluorescence intensities data from 'idat' files and performed background 41 42 subtraction, colour bias correction, and fluorescence intensities normalization using in house developed R script described elsewhere (Campanella et al. 2015). Samples were excluded if the 43 bisulphite conversion fluorescence intensity was low (i.e. less than 10,000 for both type-I and 44 type-II probes). Methylation measures were set to missing if the detection p-value was higher 45 46 than 0.01. Finally, samples and CpG sites with low call rate (<95%) were removed prior to the 47 analysis, as long with probes with non-unimodal distribution (probably methQTL sites). Probe design bias was corrected using the beta-mixture quantile (BMIQ) normalization procedure 48 implemented in the 'wateRmelon' R package (Pidsley et al. 2013). Known batch effect by plate 49

and position on the Illumina Beadchip was removed before statistical analyses using the ComBat algorithm described by Johnson et al. (ComBat function in the "sva" R package) (Leek et al. 2012). Finally, the leukocyte composition in each sample was estimated according to Houseman's method (Houseman et al. 2012). Epigenetic clocks measures were derived according with the algorithms described in the Horvath online epigenetic age calculator (https://horvath.genetics.ucla.edu/html/dnamage/).

The sample with measured DNA methlyation included individuals from five nested case-56 control studies on breast, colon, and lung cancer, lymphomas, and myocardial infarction. 57 Participants were sampled from the 47,749 participants of the EPIC Italy cohort and included 58 59 354 incident breast cancer cases, 169 incident colon cancer cases, 192 incident lung cancer cases, 72 incident lymphoma cases, 292 incident myocardial infarction cases and their 1,079 60 matched controls. Controls were individually matched on age (± 5 years), sex, season of blood 61 collection, center, and length of follow-up. We excluded cases whose diagnosis was made less 62 than one year since blood draw (N=68). Overall, after DNA methylation data quality controls 63 and sample filtering 1,803 EPIC Italian subjects were left. After excluding samples from 64 Florence center, 1,545 participants were left to use in this study. 65

Smoking was self-reported and assessed at baseline via a questionnaire. Information was collected for specific time periods (at the age of 20, 30, 40 and 50 years, approximately) and number of pack years and cigarettes per day, including the cumulative length of periods of smoke cessation for both current and former smokers (except in Naples).

Alcohol consumption was self-reported and collected at baseline. Past alcohol consumption was
 assessed as the number of glasses and types of alcoholic beverage consumed per week at
 different ages (20, 30, 40, and 50 y of age) (except in Naples).

Physical activity was collected at baseline via questionnaire. Questions included information on physical activity related to individuals' current job (sedentary, mainly standing, manual work, very heavy manual work), floor climbing, walking, biking, gardening, and physical fitness. Information on these latter activities was collected relative to winter and summer months. Energy estimates were constructed for the amount of energy expenditure for each type of activity considering the age and weight of individual participants. A cumulative index was estimated to describe activity as sport at least once a week or not.

Body mass index was collected at baseline and defined by height and weight that were measured
at enrolment with a standardized protocol. Body mass index was calculated as the ratio between
weight in kg and squared height in metres.

83 *Diabetes* was assessed at baseline, at the enrolment interview on selected medical conditions.

Hypertension was assessed at baseline at the enrolment interview on selected medical conditions and defined as present if the participant was under medical treatment, or with a measured systolic blood pressure \geq 140mmHg or diastolic blood pressure \geq 90mmHg.

Vital status was ascertained from local demographic database via automated linkage from the
population town offices and mortality registry. In LIFEPATH, follow-up of vital status is
available up to 2014.

90

91 <u>ESTHER</u>

The ESTHER study is an ongoing population-based cohort study conducted in the federal state of Saarland, Germany (Raum et al. 2007). In brief, 9,949 older adults (50-75 years) were recruited by their general practitioners (GPs) during routine health check-ups (offered every two years to people older than 35 years in the German healthcare system) between 2000 and

2002 and followed up thereafter. During the baseline enrolment, epidemiological data
(including socio-demographic characteristics, lifestyle factors, and history of major diseases)
were collected via a standardized self-administered questionnaire completed by participants and
via additional reports from participants' GPs, and biological samples (blood, stool, urine) were
obtained and stored at -80 °C. The study was approved by the ethics committees of the
University of Heidelberg and of the Medical Association of Saarland. All participants provided
written informed consent.

Education level was collected at baseline via questionnaire as no education, Hauptschule,
Realschule, Mittlere reife, Fachhochschulreife, Abitur.

DNA methylation measurements and pre-processing. DNAm in whole blood was quantified 105 using the Infinium HumanMethylation450K BeadChip (Illumina, Inc, San Diego, CA, USA) 106 107 Details of methylation analysis in the ESTHER study have been reported previously (Zhang et al. 2016). According to the manufacturer's protocol, data were normalized to internal controls 108 109 provided by Illumina (Illumina normalization). In data pre-processing, probes with detection P-110 value>0.01, with missing values>10%, probes targeting the sex chromosomes, cross-reactive probes and polymorphic CpGs55 were excluded, leaving 430,363 CpGs for genome-wide 111 112 screening. In the KORA study, data were pre-processed following the pipeline of Lehne (Lehne et al. 2015), probes with detection *P*-value (1–*P*-value computed from the background model 113 characterizing the probability that the target sequence signal was distinguishable from the 114 negative controls) >0.01 and missing values >5% were removed, and quantile normalization 115 was applied following stratification of the probe categories into six types, based on probe type 116 and colour channel, using the R package limma (Smyth 2005). Leukocyte composition was 117 estimated using the algorithms of Houseman et al. (Houseman et al. 2012). Epigenetic clocks 118 derived using the Horvath online epigenetic calculator 119 were age (https://horvath.genetics.ucla.edu/html/dnamage). 120

Two subsets of ESTHER participants were selected for DNA methylation assessment in the baseline blood samples: Subset I consisted of 1,000 participants consecutively enrolled during the first 3 months of recruitment; Subset II consisted of 864 participants selected for a casecontrol design for mortality analysis (Zhang et al. 2017). In mediation analyses, we pooled the two subsets at individual level and included an indicator variable as covariate to consider the potential differences between the two sub-cohorts.

Smoking was self-reported and assessed at baseline via a questionnaire and coded as 'Never',
'Former', or 'Current' smoker.

Alcohol consumption was self-reported and collected at baseline. Grams of daily alcohol
consumption were coded as abstainer, moderate, and high alcohol intake following WHO
standards.

Physical activity was collected at baseline via questionnaire. Participants who responded to
practice ≥2h of vigorous or light physical activity per week were classified as active, and not
active otherwise.

Body mass index was collected at baseline and defined by height and weight that were measured
at enrolment with a standardized protocol. Body mass index was calculated as the ratio between
weight in kg and squared height in metres.

Diabetes was assessed at baseline and determined from self-reported use of glucose lowering
drugs, or self-reported physician diagnosis, or measured HbA1c levels ≥6.5%, or fasting
glucose levels ≥126 mg/dL, or non-fasting glucose levels ≥200 mg/dL.

Hypertension was assessed at baseline and determined from self-reported use of antihypertensive treatment, or self-reported physician diagnosis, or measured systolic blood
pressure ≥140mmHg or diastolic blood pressure ≥90mmHg.

Vital status was ascertained from local demographic database via automated linkage from the
population town offices and mortality registry. Follow-up of vital status was available up to
2016.

147

148 <u>MCCS</u>

149 The Melbourne Collaborative Cohort Study (MCCS) has been fully described in a cohort profile(Milne et al. 2017). It is a prospective cohort study of 41,513 participants living in 150 Melbourne, Australia. Caucasian volunteers aged between 40 and 69 years were recruited 151 152 mainly from the Victorian Electoral Enrolment Register (enrolment to vote is compulsory in Australia) and the Melbourne metropolitan telephone directory. At baseline (1990–1994), 153 participants attended clinics where demographic, lifestyle and dietary information were 154 collected, and anthropometric measurements were performed. The Cancer Council Victoria's 155 Human Research Ethics Committee approved the study protocol. 156

Education was derived at baseline. Education was collected as an ordinal variable, as never attended school, attended some primary school, completed primary school, attended some high/technical school, obtained other qualification (e.g. trade certificate), completed high school or technical school, completed a tertiary degree or diploma, completed some study towards a tertiary degree or diploma.

162 DNA samples used for the present analysis were extracted from peripheral blood drawn at the 163 time of recruitment (1990–1994). For the majority (70%) of participants, the DNA source was 164 dried blood spots collected onto Guthrie Card Diagnostic Cellulose filter paper (Whatman plc, 165 Kent, United Kingdom) and stored in airtight containers at room temperature. The other sources 166 of DNA were peripheral blood mononuclear cells and buffy coats stored at -80°C for 28% and 167 2% participants, respectively. The study sample comprised Melbourne Collaborative Cohort

Study participants selected as controls in nested case-control studies of breast, colorectal, 168 kidney, lung, prostate, or urothelial cancer or mature B-cell malignancies (Severi et al. 2014, 169 Dugué et al. 2016, Wong Doo et al. 2016, Baglietto et al. 2017). Controls had been individually 170 matched to cases on age (they had to be free of cancer at an age within 1 year of the age at 171 diagnosis of the corresponding case), sex, country of birth, and blood DNA source (dried blood 172 spot, peripheral blood mononuclear cells, or buffy coat). For all but the colorectal cancer study, 173 controls were matched to cases on year of birth. For the lung cancer study, controls were 174 additionally matched on smoking status at the time of blood collection. Methods relating to 175 DNA extraction and bisulphite conversion and DNA methylation data processing have been 176 177 described in detail elsewhere (Dugué et al. 2018). Briefly, a total of 200 ng of bisulphiteconverted DNA was whole-genome amplified and hybridised onto the BeadChips. Bisulphite 178 conversion and quantification of DNA methylation with the Infinium HumanMethylation450 179 180 BeadChip were performed according to manufacturer's instructions. DNA methylation data were pre-processed and normalized using in house developed R script described elsewhere 181 (Campanella et al. 2015). Samples were excluded (N = 124) if the bisulphite conversion control 182 fluorescence intensity was less than 10,000 for both type I and type II probes. DNA methylation 183 levels were expressed as the ratio of the intensities of methylated cytosines over the total 184 185 intensities (β values). Each methylation measure was set to missing if the detection p-value was greater than 0.01; probes and samples were excluded if the total call rate was less than 95% (N 186 = 255). Additionally, the set of cross-reactive and/or polymorphic probes with minor allele 187 188 frequency higher than 0.01 in Europeans was excluded due to the low reliability of methylation measures. Forty-six samples were excluded because the estimated sex did not match the sex 189 reported by the participant. Finally, a total of N = 2,816 participants had DNA methylation data 190 available. Known batch effect by plate and position on the Illumina Beadchip was removed 191 before statistical analyses and epigenetic clock computation using the ComBat algorithm 192

described by Johnson et al. (ComBat function in the "sva" R package) (Leek et al. 2012).
Finally, the leukocyte composition in each sample was estimated according to Houseman's
method (Houseman et al. 2012).

Smoking was self-reported and assessed at baseline via a questionnaire and coded as 'Never',
'Former', or 'Current' smoker.

Alcohol was self-reported and assessed at baseline via a questionnaire that asked about beverage
specific (beer, wine, spirits) intake by unit and frequency for the current decade of life.

200 Physical activity was measured form questions relating to frequency of walking, vigorous 201 exercise (defined as exercise that induced sweat or feelings of out of breath, including swimming, tennis, netball, athletics, and running), and less vigorous exercise (defined as 202 exercise that did induce sweat or feelings of out of breath, including bike riding, dancing, etc) 203 over the last 6 months were asked. The reported frequency for each question was coded as 204 follows: 0 (none), 1.5 (one or two times per week), and 4 (three or more times per week). 205 206 Walking and less vigorous exercise frequencies were added together along with two times the frequency of vigorous exercise to generate a physical activity score for each person, in minutes 207 per week. Participants with less than 75 min/week were classified as having low physical 208 209 activity, and those with more than 75 min/week as having high physical activity.

Body mass index was assessed at baseline and follow-up and based off of height and weight
were measured at enrolment with a standardized protocol and body mass index (BMI calculated
as the ratio between weight in kg and squared height in metres).

Diabetes was assessed at baseline and follow-up and based off of self-reported diabetes status
(yes/no) and status based on blood glucose measured at baseline and self-report. For incident
cases of type 2 diabetes, 76% had their diagnosis confirmed by their doctor.

Hypertension was assessed at baseline and follow-up via self-reported high blood pressure, selfreported anti-hypertensive medication, and (average from two measures) value of systolic blood
pressure≥140 mmHg or diastolic blood pressure≥90 mmHg.

Vitality was identified by regular matching of the Melbourne Collaborative Cohort Study to cancer registries and death indices. Non-cancer, non-fatal health events were captured by following up the cohort with a mailed questionnaire and by telephone. Follow-up of vital status was available up to 2015. Participants were considered to be at risk from their index date (the date on which they reached the age at which their matched case in the corresponding nested case-control study was diagnosed with cancer) onward in order to avoid immortal time bias, as they had to be alive at this date.

226

227 <u>KORA</u>

The KORA project (Cooperative Health Research in the Region of Augsburg) consists of four independent cross-sectional surveys (S1–S4) starting between 1984 and 2001, and their respective follow-up studies (Holle et al. 2005). All participants were from the city or region of Augsburg. All participants were living in Germany and all were of European origin. For the present study, only participants in the KORA-F4 study (2006-2008) for which a DNA methylation measurement was available were included.

Genome-wide DNA methylation measurement at 485,577 genomic sites from whole-blood was
performed using the Infinium HumanMethylation450K BeadChip® (Illumina, Inc., CA, USA)
in 1,802 KORA F4 samples. These participants were chosen randomly stratified for age groups,
where older participants were oversampled compared to younger ones. Sample preparation and
measurement have been described previously (Zeilinger et al. 2013, Wilson et al. 2017).
Methylated and unmethylated signal intensities were obtained for each CpG site, which were

then converted to β -values, the ratio of the methylated signal intensity divided by the overall 240 signal intensity. DNA methylation data were pre-processed following the CPACOR pipeline 241 (Lehne et al. 2015). First, 65 probes that represent SNPs were excluded. Second, background 242 correction was performed using the R package minfi, version 1.6.0 (Aryee et al. 2014). Third, 243 detection p-values were defined as the probability of a signal being detected above the 244 background signal level, as estimated from negative control probes. Consequently, signals with 245 detection p-values ≥ 0.01 were removed, as they indicate putatively unreliable signals. 246 Similarly, signals summarized from less than three functional beads on the chip were 247 characterized as potentially unreliable and removed from the data set. Observations with less 248 249 than 95% of CpG sites providing reliable signals (75 in KORA F4) were excluded, resulting in 250 1,727 samples overall.

Data were normalized using quantile normalization on the raw signal intensities. Beta-mixture quantile normalization was performed on a stratification of the probe categories into 6 types, based on probe type and colour channel, using the R package limma, version 3.16.5 (Smyth 2005). These data were then uploaded to Horvath's online calculator to generate the various clock estimates.

Smoking was self-reported and assessed at baseline via a questionnaire. Regular and irregular smoker were coded as 'current' smoker, the remaining individuals were divided in 'former' smoker and 'never' smoker.

Alcohol consumption was collected at baseline based on average self-reported consumption (in g/day). Participants were asked how much beer, wine, and spirits they consumed on the previous weekday and weekend and were divided in 'abstainer', 'moderate' and 'high' consumption.

Physical activity was collected at baseline via questionnaire. Participants were asked how often they practice sports in summer/winter, with possible answers (1) regularly more than 2 hours a week, (2) regularly 1 to 2 hours a week, (3) less than 1 hours per week and (4) no sport in summer/winter. If the combined sum score was lower than 5, then participants were classified as 'active', and 'not active' otherwise.

Body mass index was collected at baseline and defined by height and weight, which were measured at enrolment with a standardized protocol. Body mass index was calculated as the ratio between weight in kg and squared height in metres.

Diabetes was assessed at baseline. The definition is based on a self-reported diabetes diagnosis,
which was validated by the participant's general practitioner, or antidiabetic medication intake. *Hypertension* was assessed at baseline and defined as present if the participant was under
medical treatment for hypertension, or with a measured systolic blood pressure ≥140mmHg or
diastolic blood pressure ≥90mmHg.

Vital status was ascertained from local demographic database via automated linkage from the
population town offices and mortality registry. Follow-up of vital status was available up to
278 2016.

279

280 <u>MESA</u>

The *Multi-Ethnic Study of Atherosclerosis* (MESA) enrolled 6,814 participants aged 45–84 free of cardiovascular diseases at baseline from July 2000 to July 2002 at six field centres (Baltimore, MD; Chicago, Illinois; Los Angeles, CA; New York, NY; St. Paul, MN, and Winston-Salem, NC) with ongoing follow-up. The MESA cohort is a diverse, population-based sample of 38% white, 28% black, 22% Hispanic, and 12% Asian participants, of whom half are

women. Study participants underwent extensive physical exams to determine subclinical
cardiovascular diseases and questionnaires to obtain information on sociodemographic,
lifestyle, and psychosocial factors. The MESA study protocol was approved by the Institutional
Review Boards (IRBs) at Johns Hopkins Medical Institutions, University of Minnesota,
Columbia University Medical Center, Wake Forest University Health Sciences, and University
of Washington. Analysis for this study was approved by the University of Michigan IRB. All
participants signed informed consent.

Education was assessed at baseline via questionnaire as no schooling; grades 1-8, grades 9-11,
completed high school/GED, some college but no degree, technical school certificate, associate
degree, bachelor's degree, and graduate or professional school.

296 *Race/ethnicity* was self-reported at baseline as White, Asian, Black and Hispanic.

Maternal and paternal education were collected at the second examination between 2002 and
2004. Participants reported whether their mother/father had no schooling, some schooling but
did not complete high school, high school degree, some college, college degree, graduate or
professional school.

DNA methylation was measured within the MESA Epigenomics and Transcriptomics Study. 301 302 Genome-wide methylomic and transcriptomic profiles of CD14+ purified monocytes were obtained from 1,264 randomly selected MESA participants from four MESA field centers 303 (Baltimore, MD; New York, NY; St. Paul, MN; and Winston-Salem, NC) at the 5th examination 304 (April 2010-February 2012) (Liu et al. 2013). These participants were 47% white. A detailed 305 description of the data extraction and processing procedures used for DNA methylation can be 306 307 found in Liu(Liu et al. 2013). Briefly, blood was drawn in the morning after a 12 hour fast. Monocytes were isolated using AutoMACs automated magnetic separation units (Miltenyi 308 Biotec, Bergisch Gladbach, Germany) and were consistently >90% pure. Samples were plated 309

using a stratified random sampling technique to reduce bias due to batch, chip, and position 310 effects. Methylation was measured using the Illumina HumanMethylation450 BeadChip, and 311 bead-level data were summarized in GenomeStudio. Quantile normalization was performed 312 using the *lumi* package (Du, Kibbe and Lin 2008). Quality control measures included checks 313 for sex and race/ethnicity mismatches and outlier identification by multidimensional scaling 314 plots. Criteria for elimination included: 'detected' methylation levels in <90% of MESA 315 samples (using a detection p-value threshold of 0.05) or overlap with a repetitive region. 65 316 probes that assay highly polymorphic single nucleotide polymorphisms (SNPs) rather than 317 methylation were also excluded (Pidsley et al. 2013). DNA methylation clocks were calculated 318 319 using an R script, with the exception of DNAmGrimAge, which was calculated using the Horvath online DNA Methylation Age Calculator (http://dnamage.genetics.ucla.edu/new). 320

321 *Smoking* was self-reported and assessed at the 5^{th} examination via a questionnaire.

Alcohol consumption was self-reported and collected at the 5th examination. Reported weekly consumption of red/white glasses, beer and liquor or mixed drinks were converted into alcohol units and then categorized according to WHO standards.

Physical activity was collected at the 5th examination via questionnaire- Self-reported total intentional exercise encompassing walking for exercise, dance, sports, individual activities, and conditioning were converted in MET (min/week). Participants scoring \geq 600 MET were categorized as physically active, and not physically active otherwise.

Body mass index was collected at the 5th examination and defined by height and weight that were measured at enrolment with a standardized protocol. Body mass index was calculated as the ratio between weight in kg and squared height in metres. *Diabetes* was assessed at the 5th examination, and established following the 2003 diagnostic criteria of American Diabetes Association about impaired fasting glucose, that encompassed self-reported anti-diabetic treatment and fasting glucose measurement.

335 *Hypertension* was assessed at the 5th examination defined as present if averaged second and 336 third readings of systolic blood pressure was \geq 140mmHg or of diastolic blood pressure was 337 \geq 90mmHg.

Vital status was ascertained from local demographic database via automated linkage from the
population town offices and mortality registry. Follow-up of vital status was available up to
2019.

341

342 <u>NICOLA</u>

The Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA) is a longitudinal 343 cohort representative of the non-institutionalized population of Northern Ireland 50 years and 344 older (n=8,500) (Burns et al. 2017). The study which was established in 2013 has three main 345 components: a computer aided personal interview (CAPI), a self-completion questionnaire and 346 health assessment. Dietary intake was also assessed by a food frequency questionnaire. The 347 348 CAPI was extensive in scope and included assessment of demographic, social and healthrelated factors. Measures of cardiovascular, physical, cognitive and visual function were 349 determined, and a biobank of biological samples collected. 350

Education was self-reported at baseline via questionnaire as none, some primary (not complete),
 primary or equivalent, GCSE/Intermediate/junior/group certificate or equivalent, A level/Leaving certificate or equivalent, diploma/certificate, primary degree,
 postgraduate/higher degree.

Financial situation before age 14 was self-reported at baseline as poor, about average, prettywell off financially.

357 DNA methylation measurement

All the study participants that attended the health assessment and provided a venous blood sample were analysed for DNA methylation profiles. DNAm measurement was performed from blood cells using the Illumina850K BeadChip array, using standard protocols suggested by the manufacturers. Raw methylation data were pre-processed and analysed as previously described for the EPIC Italy cohort. Epigenetic clocks measures were derived as previously described for the EPIC Italy cohort.

364 *Smoking* was self-reported and assessed at baseline via a questionnaire.

365 *Alcohol* consumption was self-reported and collected at baseline as total number of alcohol366 units per week.

367 *Physical activity* was collected at baseline via questionnaire. The sum of vigorous and moderate
368 leisure physical activities and walking activities were estimated as MET (min/week).
369 Participants scoring ≥600 MET were categorized as physically active, and not physically active
370 otherwise.

Body mass index was collected at baseline and defined by height and weight that were measured
at enrolment with a standardized protocol. Body mass index was calculated as the ratio between
weight in kg and squared height in metres.

374 *Diabetes* was assessed at baseline as self-reported intake of anti-diabetic drugs or measured
375 HbA1c levels ≥6.5%.

Hypertension was assessed at baseline as self-reported intake of anti-hypertensive drugs,
physician diagnosis, or measured systolic blood pressure ≥140mmHg or diastolic blood
pressure ≥90mmHg (average of last two readings).

Vital status was ascertained from local demographic database via automated linkage from the Business Services Organisation (BSO), an agency of the Department of Health, which uses information from the Northern Ireland Registrar General together with data from registrations and pensions to identify all deaths in Northern Ireland. Follow-up of vital status was available up to 31st May 2020.

384

385 <u>RS</u>

The *Rotterdam Study* (RS) is a prospective population-based study started in 1989. It is composed of residents of the neighbourhood of Ommoord, Rotterdam, the Netherlands, aged 45 years and over. Each participant gave an informed consent and the study was approved by the medical ethics committee of the Erasmus University Medical Center, Rotterdam, the Netherlands.

391 Data on socio-economic status, diet and lifestyle factors were assessed by standardized
392 questionnaires, measured anthropometric data and blood samples collected for DNA extraction.
393 *Education* was categorized into three groups: i) 'low' = primary school or lower; ii) 'medium'

394 = secondary school; iii) 'high' = university degree or higher.

395 DNA for methylation measurement was extracted from whole blood (stored in EDTA tubes) 396 by standardized salting out methods, from a randomly selected sample of 1,471 individuals of 397 RS second (RSII) and third (RSIII) sub-cohorts. Purified DNA was bisulfite-converted using 398 the Zymo EZ DNA Methylation kit (Zymo Research Corporation) Genome-wide DNA

methylation was measured in genomic DNA using the Illumina Infinium HumanMethylation 399 450 BeadChip (HM450) (Illumina, CA, USA), according to manufacturer's protocols. 400 Preparation and normalization of this array data was performed according to the CPACOR 401 workflow (Lehne et al. 2015). The idat files were read using the minfi package. Samples 402 showing inadequate hybridization, incomplete bisulfite treatment and gender swaps were 403 excluded. Samples were excluded if signal detection rate across probes was < 95%, leaving 404 1,420 individuals. CpG methylation proportion was reported as a normalized β-value ranging 405 from 0 to 1, where 1 represents 100% methylation. β values being outside 1.5 times the 406 interquartile range per probe were set to missing. Epigenetic clocks were estimated as described 407 for EPIC-IT. 408

Smoking was categorized as 'never', 'former' and 'current' smokers based on self-reportedinformation.

411 *Physical activity level* was measured with a self-administrated LASA Physical Activity 412 questionnaire (LAPAQ). Later, the intensity of the reported activities was quantified using the 413 metabolic equivalent of task (MET) hours per week, and then categorized in three groups: i) 414 sedentary: <10 MET hours/week; ii) moderately active: 10–40 MET hours/week and iii) active: 415 > 40 MET hours/week.

Alcohol consumption was collected using a validated semiquantitative food-frequency
questionnaire. Frequency and amount of alcohol consumed was reported.

418 Body mass index (BMI) was calculated as the ratio between weight in kg and squared height in 419 meters, and then categorized in three groups: i) normal weight: $BMI \le 25$; ii) overweight: 25 <420 $BMI \le 30$; iii) obese = $BMI \ge 30$

421 *Type 2 diabetes* cases were defined as the presence of either fasting serum glucose level \geq 7.0 422 mmol/L, physician diagnose or the use of glucose-lowering medication according to pharmacy 423 records.

424 *Hypertension* was defined as an average value (of two measurements) of \geq 140 mmHg for 425 systolic- and \geq 90 mmHg for diastolic blood pressure, or the use of antihypertensive medication, 426 according to pharmacy records.

427 *Vital status* was obtained from the municipal health authorities in Rotterdam. Follow-up of vital
428 status was available up to May 2018.

429

430 <u>TILDA</u>

The Irish Longitudinal Study on Ageing (TILDA) is a large prospective cohort study examining 431 the social, economic and health circumstances of 8,175 community-dwelling older adults aged 432 50 years and over resident in the Republic of Ireland. The sample was generated using a 3-stage 433 selection process and the Irish Geodirectory as the sampling frame. The Irish Geodirectory is a 434 comprehensive listing of all addresses in the Republic of Ireland, which is compiled by the 435 national post service and ordnance survey Ireland. Subdivisions of district electoral divisions 436 pre-stratified by socio-economic status, age, and geographical location, served as the primary 437 sampling units. The second stage involved the selection of a random sample of 40 addresses 438 439 from within each PSU resulting in an initial sample of 25,600 addresses. The third stage involved the recruitment of all members of the household aged 50 years and over. 440 Consequently, the response rate was defined as the proportion of households including an 441 eligible participant from whom an interview was successfully obtained. A response rate of 62% 442 was achieved at the household level. There were three components to the survey. Respondents 443 completed a computer-assisted personal interview and a separate self-completion paper and 444

445 pencil module which collected information that was considered sensitive. All participants were 446 invited to undergo an independent health assessment at one of two national centers using trained 447 nursing staff. Blood samples were taken during the clinical assessment with the consent of 448 participants. A more detailed exposition of study design, sample selection and protocol are 449 available elsewhere (Whelan and Savva 2013).

Education was self-reported at baseline via questionnaire as none, some primary (not complete),
primary or equivalent, intermediate/junior/group certificate or equivalent, leaving certificate or
equivalent, diploma/certificate, primary degree, postgraduate/higher degree.

453 Paternal profession during childhood was collected at baseline via questionnaire as farmer, 454 unskilled, semi-skilled, non-manual, managerial and technical, professional worker. This was 455 categorized into manual and non-manual profession to characterize paternal occupational 456 position.

DNA methylation and pre-processing. The study sample included 500 healthy individuals: 125 457 458 for each of the four SES classes: stable professional, any downward mobility, any upward mobility, and stable unskilled. Buffy coat or peripheral blood mononuclear cells samples were 459 available for all the individuals and extracted at baseline. Overall, after DNA methylation data 460 quality controls and sample filtering, 490 subjects were retained. DNA samples were extracted 461 from buffy coats using the QIAGEN GENTRA AUTOPURE LS (Qiagen, Crawley, UK). 462 Bisulphite conversion of 500 ng of each sample was performed using the EZ DNA Methylation-463 LightningTM Kit according to the manufacturer's protocol (Zymo Research, Orange, CA). Then, 464 bisulfite-converted DNA was used for hybridization on the Infinium HumanMethylation 850k 465 466 BeadChip, following the Illumina Infinium HD Methylation protocol. Briefly, a whole genome amplification step was followed by enzymatic end-point fragmentation and hybridization to 467 HumanMethylation EPIC Chip at 48°C for 17 h, followed by single nucleotide extension. The 468 incorporated nucleotides were labeled with biotin (ddCTP and ddGTP) and 2,4-dinitrophenol 469

(DNP) (ddATP and ddTTP). After the extension step and staining, the BeadChip was washed 470 471 and scanned using the Illumina HiScan SQ scanner. The intensities of the images were extracted using the GenomeStudio (v.2011.1) Methylation module (1.9.0) software, which normalizes 472 within-sample data using different internal controls that are present on the HumanMethylation 473 850k BeadChip and internal background probes. The methylation score for each CpG was 474 represented as a β-value according to the fluorescent intensity ratio representing any value 475 476 between 0 (unmethylated) and 1 (completely methylated). DNA methylation data were preprocessed and normalized using in-house software written for the R statistical computing 477 environment, including background and color bias correction, quantile normalization, and 478 479 BMIQ procedure to remove type I/type II probes bias, as described elsewhere (Teschendorff et al. 2013). DNAm levels were expressed as the ratio of the intensities of methylated cytosines 480 over the total intensities (β values). Samples were excluded (N=4) if the bisulfite conversion 481 482 control fluorescence intensity was less than 10,000 for both type I and type II probes. Methylation measures were set to missing if the detection p-value was greater than 0.01. No 483 samples were excluded because of total call rate lower than 95%. Finally, samples (N=6) were 484 excluded if the predicted sex (based on chromosome X methylation) did not match that self-485 reported. Epigenetic clocks measures were derived as previously described for EPIC-IT. 486

487 *Smoking* was self-reported and assessed at baseline via a questionnaire.

Alcohol consumption was self-reported and collected at baseline. A derived variable describing
average number of drinks per week was obtained.

490 *Physical activity* was collected at baseline via the International Physical Activity Questionnaire 491 (IPAQ) short form scoring protocol. Participants scoring moderate or high exercise intensity 492 were categorized as physically active, while participants scoring low exercise intensity were 493 assigned to being not physically active. Body mass index was collected at baseline and defined by height and weight that were measured
at enrolment with a standardized protocol. Body mass index was calculated as the ratio between
weight in kg and squared height in metres.

497 *Diabetes* was assessed at baseline via self-reported physician diagnosis or HbA1c values 498 $\geq 6.5\%$.

Hypertension was assessed at baseline via self-reported anti-hypertensive medications or a
 measured systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg.

Vital status was available from two sources: (i) through data linkage to the General Registrar's Office (GRO) National Death Registry which was done in March 2017; and (ii) via an End of Life (EOL) interview for deaths occurring subsequent to administrative record linkage, which was conducted with the respondent's next of kin (if available). Follow-up of vital status was available up to December 2018. In 11 individuals for whom date of death was not available, their date of death was estimated as last interview observation + half of the inter-wave interval (approximately 1 year).

508

509 Childhood socioeconomic conditions

Proxies of socioeconomic conditions in childhood were available in four cohort studies and 510 were included as a potential confounding in a sensitivity analysis. In EPIC-IT we dichotomized 511 512 paternal profession into manual and non-manual work as a measure of occupational position. Indeed, paternal occupational position is a commonly used indicator of socioeconomic 513 conditions in early life (Galobardes, Lynch and Smith 2007). In MESA we dichotomized 514 highest parental education into lower if participants reported parents had no schooling or some 515 schooling but did not complete, and higher otherwise. Parental education is another commonly 516 517 used indicator of socioeconomic conditions in early life (Galobardes et al. 2007). In NICOLA a question about financial situation of the parents before age 14 was categorized into poor if
participants responded poor and good if participants responded about average or pretty well off
financially. In TILDA we dichotomized paternal occupational position into manual and nonmanual work.

522

523 Harmonization of unhealthy lifestyle and morbidities

524 Self-reported smoking was classed into current, former, and never. Alcohol consumption was measured in alcohol units weekly, and we categorised participants as abstainers (0 units/week), 525 526 moderate drinkers (1-21 units/week for men, 1-14 units/week for women), or harmful drinkers (>21 units/week for men, >14 units/week for women). Height and weight were measured using 527 standard procedures; body mass index (BMI) was calculated as kg/m² and categorised as 528 normal (<25), overweight (25 to <30), or obese (≥30). Leisure physical activity was measured 529 with different questions in each study so we dichotomised it into low and high physical activity. 530 531 Hypertension and diabetes were categorized as having or not having the morbidity.

532

533 Mediation Method

We adopted a counterfactual mediation framework to disentangle direct and indirect effects of the exposure(s) on the outcome, via one or multiple mediators. Let nested counterfactual Y(a, $M(a^*)$) denote the survival age that would have been observed if exposure A were set to higher educational attainment (a) and mediator M (e.g. epigenetic ageing) to the value would have taken if exposure were set to lower educational attainment (a*). Denoting as S the sex of participants and g(t) the hazard function at age t, the total effect of exposure on outcome within levels of S is provided by

541
$$TE(a, a^*, s, t) = g\{E[Y(a, M(a))|S = s], t\} - g\{E[Y(a^*, M(a^*))|S = s], t\}$$

The above TE can be linearly decomposed into a pure direct (DE) and indirect (IE) (VanderWeele 2015, Tchetgen Tchetgen 2013) effect within levels of S that are defined by TE = DE + IE

545
$$DE(a, a^*, s, t) = g\{E[Y(a, M(a^*))|S = s], t\} - g\{E[Y(a^*, M(a^*))|S = s], t\}$$

546
$$IE(a, a^*, s, t) = g\{E[Y(a, M(a))|S = s], t\} - g\{E[Y(a, M(a^*))|S = s], t\}$$

547 The IE represents the portion of the TE explained by the chosen mediator M, whereby exposure 548 and mediator can interact in their effect on the outcome. In main analyses, we hypothesized that 549 the above effects were age-invariant.

Henceforth, we will describe the IORW method implementation for estimating above effects on the absolute scale or as hazard differences. We specified the hazard function g via the semiparametric additive hazard model, introduced by McKeague and Sasieni (McKeague and Sasieni 1994) to extend the work by Aalen (Martinussen and Sheike 2006), whereby the baseline hazard was left age-variant and non-parametrized while covariates (exposure and sex in main analyses) were parametrized as linearly additive. Namely, the parametrization of g resulted in

557
$$g(t, A, S) = \lambda_0(t) + \lambda_1 A + \lambda_2 S + \lambda_3 AS$$
(Equ. 1)

We applied the inverse odds ratio weighting (IORW) approach (Tchetgen Tchetgen 2013) to 558 559 estimate DE, IE and TE given the above choice of hazard parametrization. Briefly, the total effect corresponded to the parameter λ_1 for the exposure in the above hazard model, and was 560 estimated with the timereg (Martinussen and Sheike 2006) R package. The DE corresponded to 561 the same parameter λ_1 when the model in Equ. 1 was estimated through weighted regression, 562 whereby the chosen weights are inverse odds ratio weights considering the relationship between 563 exposure and mediator. Indeed, inverse odds ratio weighting condenses the relationship 564 between exposure and mediator using the odds ratio function as a measure of association into a 565

weight, removing the necessity to specify the regression model for the outcome on exposure and mediator, including any exposure-mediator interactions (Tchetgen Tchetgen 2013). Applying the inverse odds ratio weights renders the exposure and mediator independent, deactivating the indirect pathways involving the mediator. To estimate these weights, we parametrized the relationship between exposure and mediator with the following logistic model

571
$$logit(A) = \beta_0 + \beta_1 M + \beta_2 S + \beta_3 M S + \beta_4 Age_{baseline}$$
 (Equ. 2)

The weights were computed by taking the inverse of the predicted odds ratio for each observation in the exposed group. To achieve a more efficient estimation of DE, we further stabilized the weights by multiplying each individual's exposure-mediator odds ratio by the predicted odds of the exposure, where the mediator was evaluated at its reference value (Nguyen et al. 2015).

577 Last, the IE was estimated by taking the difference between the total effect and the direct effect578 on the scale used to obtain direct and total effects.

The required identifying conditions for IE, DE and TE within the IORW mediation approach are no model misspecification, no measurement errors of exposure, mediator and outcome, positivity, consistency and no unmeasured confounding for the effect of exposure on mediator, mediator on outcome possibly affected by exposure, and exposure on outcome (Tchetgen Tchetgen 2013, VanderWeele 2015). When all the above conditions are satisfied, the estimated effects can be interpreted as causal effects.

The IORW can be extended to study the mediating effect of multiple mediators *en-bloc* by simply adding the chosen mediators as predictors in the model for the exposure of Equ 2. This is parsimonious as there is no need to specify a model for the joint conditional density of mediators. Additionally, it has been shown that the identification of this joint IE does not depend upon the causal order of the mediators and upon unmeasured confounding of mediatormediator associations (VanderWeele and Vansteelandt 2014, Steen et al. 2017).

In summary, to obtain estimates from the IORW method we (Nguyen et al. 2015): i) fitted a 591 592 logistic regression model for education given mediator(s), age at baseline and sex, with an interaction between mediator(s) and sex; ii) computed stabilized weights for each participant 593 from the predicted odds ratios at step i; iii) estimated the direct effect via a weighted additive 594 hazard (or Cox) regression model with education, sex and their interaction as predictors; iv) 595 estimated the total effect via an additive hazard (or Cox) regression model with education, sex 596 and their interaction as predictors; v) estimate indirect effect as the difference between total and 597 direct effects; vi) generated 5,000 bootstrap draws with replacement to derive standard errors 598 for the estimands total and indirect effects. 599

Overall, the IORW method has three features that were relevant to our study: i) it does is not require to specify a model for the joint conditional density of multiple mediators but mediators can just be incorporated into the model of the exposure (e.g. Equ. 2); ii) it accommodates the potential interaction between exposure and mediator without the need to parametrize it; and iii) it offers a sensitivity analysis for unmeasured (possibly exposure-induced) confounding of the mediator-outcome relationship (Nguyen et al. 2015).

606

607 *Meta-analytic method*

We estimated total and indirect effects in each cohort study and then we pooled those estimates via the Hartung-Knapp inverse variance random effect meta-analytic model (Hartung and Knapp 2001). This method has been shown to provide reliable coverage accuracy in a small number study setting (Guolo and Varin 2017). However, since the Hartung-Knapp method can provide overly narrow confidence intervals when single-cohort effects are homogenous, we reported confidence intervals based on the fixed-effect model whenever that was the case as suggested by Wiksten et al. (Wiksten, Rücker and Schwarzer 2016). The inter-study variance τ^2 was estimated via the DerSimonian-Laird method implemented in the *meta (Schwarzer, Carpenter and Rücker 2015)* R package. The potential heterogeneity across studies was assessed through the τ^2 and I^2 statistics, the former lying between 0 and 100 with higher between-study heterogeneity corresponding to higher values. We report these statistics in the forest plots at the end of the

620 Supplementary Material.

621

622 Sensitivity analyses

We run various sensitivity analyses to investigate the robustness of our findings with respect to 623 assumptions of confounding, measurement error and age-invariant effects posited by our 624 implementation of the mediation method, and to assess whether the mediation by epigenetic 625 ageing biomarkers is related to DNA methylation levels beyond cellular heterogeneity in blood. 626 Specifically, firstly we included childhood socioeconomic conditions as a potential confounder 627 628 in a subset of four cohort studies (EPIC-IT, MESA, NICOLA, TILDA) where this information was available. This sensitivity analysis allowed us to investigate whether findings are robust 629 with respect to this potential confounding of the exposure-outcome, exposure-mediator and 630 mediator-outcome relationship. 631

Secondly, we run the sensitivity analysis proposed by Tchetgen Tchetgen and Shpitser (Tchetgen and Shpitser 2012) to assess the potential bias induced by unmeasured (possibly exposure-induced) confounding of the mediator-outcome relationship. This sensitivity analysis quantifies the potential bias in the indirect effect by offsetting the observed outcome by a value encoded in a selection bias function. We chose the selection bias function detailed in Appendix 2 of the manuscript by Nguyen et al. (Nguyen et al. 2015). This selection bias function depended on the sensitivity parameter $\rho(S)$ defined as 639 $\rho(S) = E[Y(a^*, M) | M = 1, S] - E[Y(a^*, M) | M = 0, S]$

640 whereby the mediator M (epigenetic ageing) was binary. The $\rho(S)$ captured the extent to which 641 confounding may lead to differences in the average potential survival age of participants having 642 lower educational attainment and elevated epigenetic age (epigenetic ageing > 0), compared to 643 the average potential survival age of participants having lower educational attainment and 644 mitigated epigenetic age (epigenetic ageing < 0). Thus, by varying $\rho(S)$ one may obtain a 645 sensitivity analysis for confounding of the mediator. We estimated the indirect effect for values 646 of $\rho(S)$ ranging from -5 to 5 years.

647 Thirdly, we assessed the impact of measuring epigenetic ageing biomarkers with error, as indirect effects can be biased in presence of an imperfectly measured mediator (VanderWeele, 648 Valeri and Ogburn 2012). To accommodate a non-differential measurement error in the 649 650 mediator, the model for the exposure in Equ. 2 implemented the SIMEX simulation-based approach for measurement error correction (Valeri, Lin and VanderWeele 2014). From a 651 previous validation study of reproducibility in estimating epigenetic ageing biomarkers from 652 DNA methylation in blood (McEwen et al. 2018), we hypothesized that errors were of the order 653 of 3 years. 654

Fourthly, we estimated total and indirect effects by incrementally right censoring survival age
at 70, 75, 80, and 85 years to assess the validity of findings based on our assumption of constant
effects (Stensrud and Hernán 2020).

Lastly, we applied a sequential mediation approach (VanderWeele and Vansteelandt 2014) to assess the path-specific effect mediated by epigenetic ageing biomarkers and not leukocyte composition in blood. Specifically, we estimated the indirect effect when only leukocyte composition in blood was included as a mediator in the first step, followed by an estimation of the indirect effect when both leukocyte composition and epigenetic ageing biomarkers in blood

663	were included as mediators. Given the posited causal structure in Supplementary Figure 6, a
664	substantive additional indirect effect provided by both mediators suggests epigenetic ageing
665	explains educational inequalities independently of leukocyte composition in blood, or in other
666	words that there is mediation by levels of DNA methylation in blood beyond the proportion of
667	leukocyte types in blood. We run this sensitivity analysis on all cohorts but MESA, as therein
668	DNA methylation had been measured from monocytes.
669	
670	
671	
672	
673	
674	
675	
676	
677	
677	
678	
679	
680	
681	
682	
683	

Cohort	Lower education	Higher education
EPIC-IT	None, primary school, lower secondary school,	Higher secondary school, BSc, MSc
	vocational school	
ESTHER	=< 9 years (No education, or	>=10-11 years ("secondary
	primary")	education, high school or more")
KORA	=< 9 years (No education, or primary")	>=10-11 years ("secondary education, high school or more")
MCCS	Never attended school, attended some primary school, completed primary school, obtained other qualifications such as a trade certificate, attended some high/technical school	Completed high school or technical school, completed a tertiary degree or diploma, completed some study towards a tertiary degree or diploma
MESA	No schooling; grades 1-8; grades 9-11	Completed high- school/GED; some college but not degree; technical school certificate; associate degree, bachelor's degree; graduate or professional school
NICOLA	None, some primary (not complete), Primary or equivalent, GCSE/Intermediate/junior/group certificate or equivalent, A- level/Leaving certificate or equivalent	Diploma/certificate, Primary degree, Postgraduate/higher degree
RS	Primary education; intermediate general and lower vocational education	Higher general and intermediate vocational education; higher vocational education and university
TILDA	None, some primary (not complete), Primary or equivalent, Intermediate/junior/group certificate or equivalent, Leaving certificate or equivalent	Diploma/certificate, Primary degree, Postgraduate/higher degree

Supplementary Table 1. Categorization of education.

688 **Supplementary Table 2**. Country, birth year and time-line for collection of exposure and 689 mediator data in each cohort. The reported range of birth years corresponds to the 10^{th} and 90^{th} 690 quantiles of the distribution.

Cohort	Country	Birth year	Exposure	Mediators
EPIC-IT	Italy	1933 - 1952	1993 –1998	1993 - 1998
ESTHER	Germany	1929 – 1948	2000 - 2001	2000 - 2001
KORA	Germany	1934 – 1958	1999 – 2001	2006 - 2008
MCCS	Australia	1913 – 1936	1990 – 1994	1990 – 1994
MESA	USA	1929 – 1954	2000 - 2002	2010 - 2012
NICOLA	Northern Ireland	1937 - 1962	2014 - 2016	2014 - 2016
RS	The Netherlands	1937 – 1956	2007 - 2012	2007 - 2012
TILDA	Ireland	1936 - 1958	2009 - 2011	2009 - 2011

691

692 Supplementary Table 3. Mediation by unhealthy lifestyle, morbidities, and epigenetic ageing in women. Absolute (hazard difference per 10,000 person-years) and relative (hazard 693 ratio) size of total effect of lower (vs higher) educational attainment on all-cause mortality, and 694 of indirect effects by unhealthy lifestyle and morbidities (LM) and epigenetic ageing 695 696 biomarkers (Horvath DNAmAA, Hannum DNAmAA, DNAmPhenoAA, and DNAmGrimAA). All effects are pooled estimates of single cohort's effects through a weighted 697 698 inverse variance meta-analytic model. The total number of participants/deaths across cohorts is 6,175 / 964. 699

EFFECTS	Hazard difference (95% CI)	Hazard ratio (95% CI)
Total effect	6 (-14 to 26)	1.17 (1.05 to 1.30)
Indirect effect by LM	-5 (-12 to 2)	1.02 (0.94 to 1.11)
Indirect effect by LM and Horvath DNAmAA	-4 (-10 to 2)	1.03 (0.98 to 1.02)
Indirect effect by LM and Hannum DNAmAA	-5 (-11 to 2)	1.02 (0.93 to 1.12)
Indirect effect by LM and DNAmPhenoAA	-5 (-11 to 1)	1.02 (0.95 to 1.09)
Indirect effect by LM and DNAmGrimAA	-3 (-11 to 4)	1.03 (0.95 to 1.12)

700

701

702

703

704

705

706

707

708

709

710

Supplementary Table 4. Potential confounding by childhood socioeconomic conditions.

Absolute effects quantifying total effect of education (lower vs higher) on all-cause mortality and indirect effect by epigenetic ageing biomarkers (Horvath DNAmAA, Hannum DNAmAA,


DNAmPhenoAA, and DNAmGrimAA) when childhood socioeconomic conditions (CSC) were included as an additional potential confounding. All effects are pooled estimates of single

- cohort's hazard ratios through a weighted inverse variance meta-analytic model. The total
- number of participants/deaths across EPIC-IT, MESA, NICOLA, and TILDA cohorts is 2,370
- / 290 for men and 2,674 / 225 for women.

EFFECTS	Men		Women	
	Without CSC	With CSC	Without CSC	With CSC
Total effect	56 (32 to 79)	57 (28 to 85)	6 (-11 to 23)	6 (-11 to 24)
Indirect effect by Horvath DNAmAA	12 (4 to 20)	13 (8 to 17)	-5 (-8 to -1)	-4 (-7 to -1)
Indirect effect by Hannum DNAmAA	17 (9 to 25)	19 (12 to 25)	-5 (-9 to -1)	-4 (-9 to 0)
Indirect effect by DNAmPhenoAA	19 (9 to 30)	21 (14 to 27)	-5 (-8 to -2)	-5 (-8 to -2)
Indirect effect by DNAmGrimAA	29 (21 to 38)	30 (22 to 38)	-1 (-15 to 13)	1 (-13 to 14)


Supplementary Table 5. Path-specific indirect effect by epigenetic ageing independent of leukocyte composition in men. Absolute (hazard difference per 10,000 person-years) size of total effect of lower (vs higher) educational attainment on all-cause mortality, and for indirect effects by leukocyte composition (LC) and epigenetic ageing in blood. Four epigenetic ageing biomarkers based on different epigenetic clocks estimators are reported: Horvath DNAmAA, Hannum DNAmAA, DNAmPhenoAA, and DNAmGrimAA. All effects are pooled estimates of single cohort's hazards through a weighted inverse variance meta-analytic model. The study MESA is not included as therein epigenetic ageing biomarkers were computed from DNA methylation in monocytes. The total number of participants/deaths across cohorts is 5,865 / 1,559.

EFFECTS	Hazard difference (95% CI)
Total effect	57 (39 to 74)
Indirect effect by LC	16 (10 to 22)
Indirect effect by LC and Horvath DNAmAA	15 (8 to 22)
Indirect effect by Horvath DNAmAA but not LC	0 (-1 to 1)
Indirect effect by LC and Hannum DNAmAA	18 (12 to 24)
Indirect effect by Hannum DNAmAA but not LC	2 (0 to 4)
Indirect effect by LC and DNAmPhenoAA	21 (14 to 27)
Indirect effect by DNAmPhenoAA but not LC	5 (2 to 7)
Indirect effect by LC and DNAmGrimAA	34 (26 to 43)
Indirect effect by DNAmGrimAA and not LC	18 (10 to 25)



754

Supplementary Figure 1. Indirect effect by epigenetic ageing biomarker DNAmGrimAA 755 in men as a function of bias (ρ) in the outcome due to unmeasured confounding of the 756 757 mediator-outcome relationship. Rho represents the counterfactual difference in average survival age for being exposed to lower education and elevated epigenetic age (positive values 758 of DNAmGrimAA) compared to being exposed to lower education and mitigated epigenetic 759 age (negative values of DNAmGrimAA). A positive value of p indicates a delayed survival age 760 due to a hypothetical intervention for slowing or mitigating epigenetic ageing, while a negative 761 value indicates the opposite. Pooled excess deaths per 10,000 person-years and 95% 762 compatibility intervals (CI) are reported. All effects are pooled estimates of single cohort's 763 hazard differences through a weighted inverse variance meta-analytic model. The total number 764 of participants/deaths across cohorts is 6,477 / 1,638. 765



767


768 Supplementary Figure 2. Educational inequalities and mediation by epigenetic ageing

biomarkers on the absolute scale when considering a potential measurement error of three
 years in the assessment of the biomarkers. Excess deaths per 10,000 person-years and 95%
 compatibility intervals (CI) are reported for the total effect of lower (vs higher) educational


compatibility intervals (CI) are reported for the total effect of lower (vs higher) educational
 attainment on all-cause mortality, and for the indirect effect by epigenetic ageing biomarkers

(Horvath DNAmAA, Hannum DNAmAA, DNAmPhenoAA, and DNAmGrimAA). All effects

- are pooled estimates of single cohort's hazard differences through a weighted inverse variance
- meta-analytic model. The total number of participants/deaths across cohorts is 6,477 / 1,638 for
- 776 men and 6,544 / 1,002 for women.




Supplementary Figure 3. Educational inequalities and mediation by epigenetic ageing biomarkers on the relative scale when considering a potential measurement error of three years in the assessment of the biomarkers. Hazard ratios and 95% compatibility intervals (CI) are reported for the total effect of lower (vs higher) educational attainment on all-cause mortality, and for the indirect effect by epigenetic ageing biomarkers (Horvath DNAmAA, Hannum DNAmAA, DNAmPhenoAA, and DNAmGrimAA). All effects are pooled estimates of single cohort's hazard ratios through a weighted inverse variance meta-analytic model. The total number of participants/deaths across cohorts is 6,477 / 1,638 for men and 6,544 / 1,002 for women.



Supplementary Figure 4. Educational inequalities and mediation by epigenetic ageing biomarkers on the absolute scale at incremental right censoring values of survival age.

Hazard difference per 10,000 person-years and 95% compatibility intervals (CI) are reported 795 for the total effect of lower (vs higher) educational attainment on all-cause mortality, and for 796 indirect effect by epigenetic ageing biomarkers (Horvath DNAmAA, Hannum DNAmAA, 797 DNAmPhenoAA, and DNAmGrimAA) when survival age is right censored at 70y, 75y, 80y, 798 and 85y (upper left, upper right, lower left, lower right panels, respectively). All effects are 799 800 pooled estimates of single cohort's hazard differences through a weighted inverse variance meta-analytic model. The total number of participants/deaths across cohorts is 6,477 / 1,638 for 801 men and 6,544 / 1,002 for women. 802


803



Supplementary Figure 5. Educational inequalities and mediation by epigenetic ageing 806 biomarkers on the relative scale at incremental right censoring values of survival age. 807 808 Hazard ratios and 95% compatibility intervals (CI) are reported for the total effect of lower (vs higher) educational attainment on all-cause mortality, and for indirect effect by epigenetic 809 ageing biomarkers (Horvath DNAmAA, Hannum DNAmAA, DNAmPhenoAA, and 810 DNAmGrimAA) when survival age is right censored at 70y, 75y, 80y, and 85y (upper left, 811 upper right, lower left, lower right panels, respectively). All effects are pooled estimates of 812 single cohort's hazard ratios through a weighted inverse variance meta-analytic model. The 813 total number of participants/deaths across cohorts is 6,477 / 1,638 for men and 6,544 / 1,002 814 for women. 815

816

817



820 Supplementary Figure 6. Causal structure to assess the path-specific effect of epigenetic 821 ageing biomarkers independent of leukocyte composition in blood. For the sake of 822 simplicity, we do not draw confounders (age and sex). Educational attainment represents the 823 exposure and all-cause mortality the outcome. Leukocyte composition in blood and DNA 824 methylation-based epigenetic ageing in blood are the mediators.

- - -

839 Forest Plots

Study	Total Effect in Men	HD	95% CI	Weight (fixed)	Weight (random)
EPIC-IT		75.8	[35.7; 115.9]	18.6%	18.6%
ESTHER		67.7	[16.0; 119.4]	11.2%	11.2%
KORA		33.8	[-15.4; 83.0]	12.4%	12.4%
MCCS	÷	54.3	[9.7; 98.9]	15.1%	15.1%
MESA	← ∗	-1.9	[-113.0; 109.2]	2.4%	2.4%
NICOLA		49.6	[18.0; 81.2]	30.0%	30.0%
RS	\rightarrow	56.5	[-14.5; 127.5]	5.9%	5.9%
TILDA		64.0	[-18.9; 146.9]	4.4%	4.4%
Fixed effect model		55.0	[37.7; 72.3]	100.0%	
Random effect model		55.0	[41.0; 69.0]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$					
	-20 0 20 40 60 80 100 120				
	Hazard difference [10,000 person-years]				
				Weight	Weight
Study	Total Effect in Women	HD	95% CI	Weight (fixed)	Weight (random)
Study EPIC-IT	Total Effect in Women ← 📑 🕂 ──	HD -2.2	95% CI [-28.6; 24.2]	•	•
	Total Effect in Women ← 글 : ←			(fixed)	(random)
EPIC-IT	Total Effect in Women	-2.2	[-28.6; 24.2]	(fixed) 18.3%	(random) 18.3%
EPIC-IT ESTHER	Total Effect in Women	-2.2 12.3	[-28.6; 24.2] [-27.3; 51.9]	(fixed) 18.3% 8.1%	(random) 18.3% 8.1%
EPIC-IT ESTHER KORA	Total Effect in Women	-2.2 12.3 8.9	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4]	(fixed) 18.3% 8.1% 10.1%	(random) 18.3% 8.1% 10.1%
EPIC-IT ESTHER KORA MCCS	Total Effect in Women	-2.2 12.3 8.9 18.8	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3]	(fixed) 18.3% 8.1% 10.1% 6.4%	(random) 18.3% 8.1% 10.1% 6.4%
EPIC-IT ESTHER KORA MCCS MESA	Total Effect in Women	-2.2 12.3 8.9 18.8 7.4	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3] [-68.4; 83.2]	(fixed) 18.3% 8.1% 10.1% 6.4% 2.2%	(random) 18.3% 8.1% 10.1% 6.4% 2.2%
EPIC-IT ESTHER KORA MCCS MESA NICOLA	Total Effect in Women	-2.2 12.3 8.9 18.8 7.4 11.8	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3] [-68.4; 83.2] [-5.4; 29.0]	(fixed) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3%	(random) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS	Total Effect in Women	-2.2 12.3 8.9 18.8 7.4 11.8 -28.0	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3] [-68.4; 83.2] [-5.4; 29.0] [-67.5; 11.5]	(fixed) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2%	(random) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA	Total Effect in Women	-2.2 12.3 8.9 18.8 7.4 11.8 -28.0 52.4	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3] [-68.4; 83.2] [-5.4; 29.0] [-67.5; 11.5] [-9.4; 114.2]	(fixed) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2% 3.3%	(random) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model		-2.2 12.3 8.9 18.8 7.4 11.8 -28.0 52.4 7.4	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3] [-68.4; 83.2] [-5.4; 29.0] [-67.5; 11.5] [-9.4; 114.2] [-3.8; 18.7]	(fixed) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2% 3.3%	(random) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2% 3.3%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model	Total Effect in Women	-2.2 12.3 8.9 18.8 7.4 11.8 -28.0 52.4 7.4	[-28.6; 24.2] [-27.3; 51.9] [-26.6; 44.4] [-25.7; 63.3] [-68.4; 83.2] [-5.4; 29.0] [-67.5; 11.5] [-9.4; 114.2] [-3.8; 18.7]	(fixed) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2% 3.3%	(random) 18.3% 8.1% 10.1% 6.4% 2.2% 43.3% 8.2% 3.3%

840


841 Supplementary Figure 7. Forest plots of the total effect of educational attainment on all-842 cause mortality in men (top) and women (bottom) on the absolute scale. Hazard difference 843 (HD) per 10,000 person-years and 95% compatibility intervals (CI) are reported. Weight 844 represents the contribution of each study to the pooled estimates (diamond) as computed by the 845 fixed/random meta-analytic effect model. Heterogeneity across studies is quantified by I^2 and 846 τ^2 .

		Weight	Weight
Study	Indirect Effect by Horvath DNAmAA HD 95% C	l (fixed)	(random)
EPIC-IT	6.4 [-6.8; 19.6] 10.5%	10.5%
ESTHER	17.4 [4.5; 30.3] 11.0%	11.0%
KORA	10.9 [-4.7; 26.5] 7.5%	7.5%
MCCS	11.7 [3.6; 19.8] 27.7%	27.7%
MESA	-17.8 [-85.3; 49.7] 0.4%	0.4%
NICOLA	13.1 [6.2; 20.0] 38.3%	38.3%
RS	→ 35.5 [6.7; 64.3] 2.2%	2.2%
TILDA	* 18.2 [-9.8; 46.2] 2.3%	2.3%
Fixed effect mode	12.8 [8.5; 17.1] 100.0%	
Random effect mo	del 12.8 [8.5; 17.1]	100.0%
$I^2 = 0.0\%, \tau^2 = 0$			
	-10 0 10 20 30 40 50		
	Hazard difference [10,000 person-years]		
		Weight	Weight
Study	Indirect Effect by Hannum DNAmAA HD 95% C	l (fixed)	(random)

EPIC-IT		-		<u> </u>	-			13.7	[1.5; 25.9]	13.6%	13.6%
ESTHER			-	÷				17.4	[4.8; 30.0]	13.0%	13.0%
KORA		-	-					12.8	[-3.1; 28.7]	8.1%	8.1%
MCCS			-					14.8	[6.0; 23.6]	26.2%	26.2%
MESA	←	_				_		6.6	[-22.9; 36.2]	2.3%	2.3%
NICOLA			-		-			19.9	[11.8; 28.0]	31.4%	31.4%
RS				-			→	33.4	[5.5; 61.3]	2.6%	2.6%
TILDA		_					-	18.6	[-9.0; 46.2]	2.7%	2.7%
Fixed effect model			<	\diamond				16.8	[12.3; 21.3]	100.0%	
Random effect mod	lel		<	\diamond				16.8	[13.2; 20.5]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$			1		1	I					
	-10	0	10	20	30	40	50				

Hazard difference [10,000 person-years]

Study	Indirect Effect by DNAmPhenoAA	HD	95% CI	Weight (fixed)	Weight (random)
EPIC-IT		13.5	[-0.4; 27.4]	13.6%	13.6%
ESTHER		27.4	[10.4; 44.4]	9.0%	9.0%
KORA		19.3	[1.5; 37.1]	8.2%	8.2%
MCCS		15.0	[5.3; 24.7]	27.6%	27.6%
MESA	← +	11.9	[-22.9; 46.7]	2.2%	2.2%
NICOLA		22.0	[13.2; 30.8]	33.7%	33.7%
RS		37.1	[7.0; 67.2]	2.9%	2.9%
TILDA		25.8	[-4.9; 56.5]	2.8%	2.8%
Fixed effect model		19.5	[14.4; 24.6]	100.0%	
Random effect mod	lel 🔆	19.5	[14.6; 24.4]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$					
	-10 0 10 20 30 40 50				
	Hazard difference [10,000 person-years]				
				Maight	Moight




847

848 Supplementary Figure 8. Forest plots of the indirect effect by epigenetic ageing biomarkers in men on the absolute scale. Hazard difference (HD) per 10,000 person-years 849 and 95% compatibility intervals (CI) are reported. Weight represents the contribution of each 850 study to the pooled estimates (diamond) as computed by the fixed/random meta-analytic effect 851 model. Heterogeneity across studies is quantified by I^2 and τ^2 . 852

Study	Indirect Effect by Horvath DNAmAA	HD	95% CI	Weight (fixed)	Weight (random)
EPIC-IT		-5.9	[-11.5; -0.3]	26.6%	26.6%
ESTHER	<u> </u>	-2.5	[-11.4; 6.4]	10.4%	10.4%
KORA		-4.4	[-16.0; 7.1]	6.2%	6.2%
MCCS	- <u>i</u>	-3.5	[-11.6; 4.6]	12.5%	12.5%
MESA	Ť	-11.6	[-38.8; 15.5]	1.1%	1.1%
NICOLA	<u> </u>	-3.3	[-7.9; 1.3]	39.7%	39.7%
RS		-10.7	[-29.1; 7.7]	2.4%	2.4%
TILDA		10.5	[-17.0; 38.0]	1.1%	1.1%
TILDA		10.5	[-17.0, 50.0]	1.170	1.170
Fixed effect model	ı 🖕	-4.1	[-7.0; -1.3]	100.0%	
Random effect mo		-4.1	[-6.2; -2.0]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$,,		
	-40 -20 0 20 40				
	Hazard difference [10,000 person-years]				
				Weight	Weight
Study	Indirect Effect by Hannum DNAmAA	HD	95% CI	(fixed)	(random)
EPIC-IT		-7.1	[-12.0; -2.2]	32.9%	32.9%
ESTHER	- <u>ja</u>	-2.1	[-11.0; 6.8]	9.9%	9.9%
KORA		-3.8	[-15.5; 7.9]	5.6%	5.6%
MCCS		-3.6	[-12.0; 4.8]	11.1%	11.1%
MESA		-10.0	[-39.5; 19.6]	0.9%	0.9%
NICOLA	복	-3.3	[-7.9; 1.3]	36.1%	36.1%
RS	+ <u>+</u> +-	-12.7	[-30.1; 4.7]	2.6%	2.6%
TILDA		11.8	[-15.7; 39.4]	1.0%	1.0%
Fixed effect model	\$	-4.6	[-7.4; -1.9]	100.0%	
Random effect mod		-4.6	[-7.2; -2.1]		100.0%
$l^2 = 0.0\%, \tau^2 = 0$	-40 -20 0 20 40				
	Hazard difference [10,000 person-years]				
				Weight	Weight
Study	Indirect Effect by DNAmPhenoAA	HD	95% CI	(fixed)	(random)
EPIC-IT		-5.3	[-10.9; 0.3]	28.5%	28.5%
ESTHER		-4.3	[-14.2; 5.6]	9.1%	9.1%
KORA	<u> </u>	-4.0	[-15.9; 7.8]	6.3%	6.3%
MCCS		-4.6	[-12.5; 3.3]	14.4%	14.4%
MESA	T	-13.4	[-39.2; 12.5]	1.3%	1.3%
NICOLA	÷	-4.2	[-9.2; 0.8]	36.0%	36.0%
RS		-18.1	[-34.8; -1.4]	3.2%	3.2%
TILDA		10.6	[-16.4; 37.6]	1.2%	1.2%
Fixed effect model	\$	-5.0	[-7.9; -2.0]	100.0%	
Random effect mod		-5.0	[-7.7; -2.2]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$	-40 -20 0 20 40				
	Hazard difference [10,000 person-years]				
Study	Indirect Effect by DNAmGrimAA	HD	95% CI	Weight (fixed)	Weight (random)
	and l			05 001	00 001
EPIC-IT		-4.7	[-10.7; 1.3]	35.6%	28.8%
ESTHER	i i	-7.6	[-20.3; 5.2]	8.0%	10.2%
KORA	- 2	-1.3	[-13.5; 10.9]	8.8%	11.1%
MCCS		-4.5	[-13.5; 4.5]	15.9%	17.5%
MESA		-16.5	[-48.5; 15.5]	1.3%	1.9%
NICOLA		6.1	[-1.0; 13.2]	25.8%	24.0%
RS TILDA		-12.6	[-30.8; 5.6]	3.9%	5.5%
TILDA		-8.0	[-51.7; 35.7]	0.7%	1.0%
Fixed effect model		-2.3	[-5.9; 1.3]	100.0%	
Random effect mod	lel 🕹	-2.7	[-7.8; 2.4]		100.0%
$l^2 = 21.9\%, \tau^2 = 8.7$,		1001070
	-40 -20 0 20 40				
	Hazard difference [10,000 person-years]				

855 Supplementary Figure 9. Forest plots of the absolute indirect effect by epigenetic ageing 856 biomarkers in women on the absolute scale. Hazard difference (HD) per 10,000 person-years 857 and 95% compatibility intervals (CI) are reported. Weight represents the contribution of each 858 study to the pooled estimates (diamond) as computed by the fixed/random meta-analytic effect 859 model. Heterogeneity across studies is quantified by I^2 and τ^2 .

Study	Total Effect in Men	log(HR)	95% CI	Weight (fixed)	Weight (random)
EPIC-IT		0.67	[0.27; 1.07]	7.4%	7.4%
ESTHER		0.31	[0.07; 0.54]	21.2%	21.2%
KORA		0.25	[-0.22; 0.71]	5.5%	5.5%
MCCS		0.15	[-0.01; 0.31]	48.0%	48.0%
MESA ←		-0.05	[-0.79; 0.68]	2.2%	2.2%
NICOLA		0.38	[-0.20; 0.95]	3.6%	3.6%
RS		0.21	[-0.23; 0.65]	6.1%	6.1%
TILDA		0.21	[-0.23; 0.65]	6.1%	6.1%
Fixed effect model		0.24	[0.13; 0.35]	100.0%	
Random effect model	·	0.24	[0.11; 0.37]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$					
-0.5	0 0.5 1				
	Hazard ratio [log]				



861 Supplementary Figure 10. Forest plots of the relative effect of educational attainment on 862 all-cause mortality in men (top) and women (bottom) on the relative scale. Hazard ratio 863 (HR) and 95% compatibility intervals (CI) are reported. Weight represents the contribution of 864 each study to the pooled estimates (diamond) as computed by the fixed/random meta-analytic 865 effect model. Heterogeneity across studies is quantified by I^2 and τ^2 .

Study Ind	lirect Effect by Horvath DNAmAA	Vog(HR)	95% CI	Weight (fixed)	Weight (random)
EPIC-IT	+	-0.02	[-0.11; 0.07]	3.2%	3.2%
ESTHER	+	-0.00	[-0.04; 0.03]	19.6%	19.6%
KORA	.	0.02	[-0.10; 0.13]	1.8%	1.8%
MCCS	+	0.00	[-0.01; 0.02]	68.3%	68.3%
MESA		-0.11	[-0.46; 0.23]	0.2%	0.2%
NICOLA	_ +	0.01	[-0.07; 0.09]	3.9%	3.9%
RS	_	-0.02	[-0.15; 0.10]	1.5%	1.5%
TILDA		-0.02	[-0.15; 0.10]	1.5%	1.5%
Fixed effect model	4	0.00	[-0.01; 0.02]	100.0%	
Random effect model		0.00	[-0.01; 0.01]		100.0%
$I^2 = 0.0\%, \tau^2 = 0$	-0.4 -0.2 0 0.2 0.4				
	Hazard ratio [log]			Weight	Weight
Study Inc	lirect Effect by Hannum DNAmA/	Alog(HR)	95% CI	(fixed)	(random)
EPIC-IT		0.03	[-0.05; 0.11]	4.7%	4.7%
ESTHER	+	-0.01	[-0.04; 0.02]	29.0%	29.0%
KORA	_ 	0.04	[-0.08; 0.16]	2.1%	2.1%
MCCS	÷	0.01	[-0.01; 0.04]	56.3%	56.3%
MESA		0.03	[-0.17; 0.22]	0.8%	0.8%
NICOLA	+	0.07	[-0.03; 0.17]	3.2%	3.2%
RS		-0.04	[-0.16; 0.09]	2.0%	2.0%
TILDA		-0.04	[-0.16; 0.09]	2.0%	2.0%
Fixed effect model	•	0.01	[-0.01; 0.03]	100.0%	
Random effect model $I^2 = 0.0\%, \tau^2 = 0$		0.01	[-0.01; 0.03]		100.0%
$T = 0.0\%, \tau = 0$	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]				
				Weight	Weight
Study In	direct Effect by DNAmPhenoAA	log(HR)	95% CI	(fixed)	(random)
	ndirect Effect by DNAmPhenoAA			(fixed)	(random)
EPIC-IT	direct Effect by DNAmPhenoAA	0.03	[-0.06; 0.12]	(fixed) 5.3%	(random) 5.3%
EPIC-IT ESTHER	Idirect Effect by DNAmPhenoAA	0.03 0.04	[-0.06; 0.12] [-0.02; 0.10]	(fixed) 5.3% 13.4%	(random) 5.3% 13.4%
EPIC-IT ESTHER KORA	Indirect Effect by DNAmPhenoAA	0.03 0.04 0.10	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24]	(fixed) 5.3% 13.4% 2.3%	(random) 5.3% 13.4% 2.3%
EPIC-IT ESTHER KORA MCCS	Indirect Effect by DNAmPhenoAA	0.03 0.04 0.10 0.02	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04]	(fixed) 5.3% 13.4% 2.3% 69.1%	(random) 5.3% 13.4% 2.3% 69.1%
EPIC-IT ESTHER KORA MCCS MESA		0.03 0.04 0.10 0.02 0.07	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2%	(random) 5.3% 13.4% 2.3% 69.1% 1.2%
EPIC-IT ESTHER KORA MCCS MESA NICOLA	Indirect Effect by DNAmPhenoAA	0.03 0.04 0.10 0.02 0.07 0.09	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9%
EPIC-IT ESTHER KORA MCCS MESA		0.03 0.04 0.10 0.02 0.07	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2%	(random) 5.3% 13.4% 2.3% 69.1% 1.2%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS		0.03 0.04 0.10 0.02 0.07 0.09 -0.01	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model		0.03 0.04 0.10 0.02 0.07 0.09 -0.01 -0.01	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model	-0.4 -0.2 0 0.2 0.4	0.03 0.04 0.10 0.02 0.07 0.09 -0.01 -0.01 0.02	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model		0.03 0.04 0.10 0.02 0.07 0.09 -0.01 -0.01 0.02	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%$, $\tau^2 = 0$	-0.4 -0.2 0 0.2 0.4	0.03 0.04 0.10 0.02 0.07 -0.09 -0.01 -0.01 0.02 0.02	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%$, $\tau^2 = 0$	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.10 0.02 0.07 -0.09 -0.01 -0.01 0.02 0.02	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% -	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.10 0.02 0.07 -0.01 -0.01 0.02 0.02 0.02	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% 	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (random)
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$ Study	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 -0.01 -0.01 0.02 0.02 0.02 log(HR) 0.16	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.01; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.05; 0.26]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 2.4% 2.4% 100.0% Weight (fixed) 8.3%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (random) 13.0%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 log(HR) 0.16 0.20	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.05; 0.26] [0.11; 0.28]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 2.4% 2.4% 2.4% 100.0% Weight (fixed) 8.3% 12.5%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 2.4% 100.0% Weight (random) 13.0% 17.7%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model $I^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.10 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 0.02 log(HR) 0.16 0.20 0.17	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.05; 0.26] [0.11; 0.28] [0.02; 0.32]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (random) 13.0% 17.7% 7.0%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $l^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 log(HR) 0.16 0.20 0.17 0.08	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.1; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.05; 0.26] [0.11; 0.28] [0.02; 0.32] [0.04; 0.11]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0% 63.7%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% - 100.0% Weight (random) 13.0% 17.7% 7.0% 41.9%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS MESA	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 log(HR) 0.16 0.20 0.17 0.08 0.07	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.1; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.05; 0.26] [0.11; 0.28] [0.02; 0.32] [0.04; 0.11] [-0.20; 0.34]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0% 63.7% 1.3%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS MESA NICOLA	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 -0.01 -0.01 0.02 0.02 0.02 log(HR) 0.16 0.20 0.17 0.8 0.07 0.15	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.01; 0.26] [0.11; 0.28] [0.02; 0.32] [0.04; 0.11] [-0.20; 0.34] [0.00; 0.03]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% - Weight (fixed) 8.3% 12.5% 4.0% 63.7% 1.3% 4.2%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 2.4% 100.0% Weight (random) 13.0% 17.7% 7.0% 41.9% 2.5% 7.2%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS MESA NICOLA RS	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 0.02 log(HR) 0.16 0.20 0.17 0.08 0.07 0.15 0.06	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% Cl [0.05; 0.26] [0.11; 0.28] [0.02; 0.32] [0.02; 0.32] [0.04; 0.11] [-0.20; 0.34] [0.00; 0.30] [-0.11; 0.24]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0% 63.7% 1.3% 4.2% 3.0%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (random) 13.0% 17.7% 7.0% 41.9% 2.5% 7.2% 5.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model $I^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 -0.01 -0.01 0.02 0.02 0.02 log(HR) 0.16 0.20 0.17 0.08 0.07 0.15 0.06 0.06	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [-0.14; 0.13] [0.00; 0.05] [0.01; 0.04] 95% C! [0.05; 0.26] [0.11; 0.28] [0.02; 0.32] [0.04; 0.11] [-0.20; 0.34] [0.00; 0.30] [-0.11; 0.24] [-0.11; 0.24]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0% 63.7% 1.3% 4.2% 3.0% 3.0%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 2.4% 100.0% Weight (random) 13.0% 17.7% 7.0% 41.9% 2.5% 7.2% 5.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model $t^2 = 0.0\%, t^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 log(HR) 0.16 0.20 0.17 0.08 0.07 0.15 0.06 0.06 0.06	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.1; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.01; 0.04] 95% Cl [0.01; 0.04] [0.01; 0.26] [0.11; 0.28] [0.02; 0.32] [0.04; 0.11] [-0.20; 0.34] [0.00; 0.30] [-0.11; 0.24] [-0.11; 0.24] [-0.11; 0.24] [-0.7; 0.13]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0% 63.7% 1.3% 4.2% 3.0% 3.0%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 100.0% Weight (random) 13.0% 17.7% 7.0% 41.9% 2.5% 7.2% 5.4% 5.4%
EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model $R^2 = 0.0\%, \tau^2 = 0$ Study I EPIC-IT ESTHER KORA MCCS MESA NICOLA RS TILDA Fixed effect model Random effect model	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]	0.03 0.04 0.02 0.07 0.09 -0.01 -0.01 0.02 0.02 log(HR) 0.16 0.20 0.17 0.08 0.07 0.15 0.06 0.06 0.06	[-0.06; 0.12] [-0.02; 0.10] [-0.03; 0.24] [-0.1; 0.04] [-0.13; 0.26] [-0.02; 0.19] [-0.14; 0.13] [-0.14; 0.13] [0.01; 0.04] 95% Cl [0.01; 0.04] [0.01; 0.26] [0.11; 0.28] [0.02; 0.32] [0.04; 0.11] [-0.20; 0.34] [0.00; 0.30] [-0.11; 0.24] [-0.11; 0.24] [-0.11; 0.24] [-0.7; 0.13]	(fixed) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 100.0% Weight (fixed) 8.3% 12.5% 4.0% 63.7% 1.3% 4.2% 3.0% 3.0%	(random) 5.3% 13.4% 2.3% 69.1% 1.2% 3.9% 2.4% 2.4% 7.0% 4100.0% 13.0% 17.7% 7.0% 41.9% 2.5% 7.2% 5.4% 5.4%

868 Supplementary Figure 11. Forest plots of the relative indirect effect by epigenetic ageing 869 biomarkers in men on the relative scale. Hazard ratio (HR) and 95% compatibility intervals 870 (CI) are reported. Weight represents the contribution of each study to the pooled estimates 871 (diamond) as computed by the fixed/random meta-analytic effect model. Heterogeneity across 872 studies is quantified by I^2 and τ^2 .

Study	Indirect Effect by Horvath DNAmAAo	og(HR)	95% CI	Weight (fixed)	Weight (random)
EPIC-IT	- 	-0.05	[-0.12; 0.02]	13.0%	17.8%
ESTHER		0.04	[0.00; 0.08]	30.9%	28.1%
KORA		0.03	[-0.11; 0.16]	3.0%	5.8%
MCCS	÷	0.02	[-0.01; 0.06]	44.9%	32.2%
MESA		-0.09	[-0.31; 0.12]	1.3%	2.6%
NICOLA		0.03	[-0.10; 0.15]	3.5%	6.5%
RS		0.15	[-0.03; 0.33]	1.7%	3.5%
TILDA		0.15	[-0.03; 0.33]	1.7%	3.5%
Fixed effect model	¢	0.02	[0.00; 0.05]	100.0%	
Random effect mode	əl le	0.02	[-0.02; 0.07]		100.0%
$I^2 = 30.7\%, \tau^2 = 0.0007$					
	-0.4 -0.2 0 0.2 0.4				
	Hazard ratio [log]				

Study	Indirect Effect by Hannum DNAm	AAlog(HR)	95% CI	(fixed)	(random)
EPIC-IT		-0.07	[-0.12; -0.01]	16.2%	20.0%
ESTHER	<u>+</u>	0.04	[0.00; 0.07]	37.1%	27.6%
KORA		0.04	[-0.10; 0.17]	3.0%	6.4%
MCCS	÷	0.02	[-0.02; 0.06]	35.1%	27.1%
MESA		-0.07	[-0.31; 0.18]	0.9%	2.3%
NICOLA		0.03	[-0.09; 0.15]	3.8%	7.8%
RS		0.11	[-0.06; 0.28]	1.9%	4.4%
TILDA	-	0.11	[-0.06; 0.28]	1.9%	4.4%
Fixed effect model	•	0.02	[-0.01; 0.04]	100.0%	-
Random effect mod $l^2 = 40.1\%, \tau^2 = 0.001$		0.02	[-0.03; 0.06]		100.0%
	-0.4 -0.2 0 0.2 0.4 Hazard ratio [log]				

Weight

Weight

Study	Indirect Effect by DNAmPhenoAA	log(HR)	95% CI	Weight (fixed)	Weight (random)
EPIC-IT		-0.04	[-0.11; 0.03]	12.6%	12.6%
ESTHER	-	0.03	[-0.02; 0.08]	22.8%	22.8%
KORA		0.04	[-0.10; 0.18]	3.0%	3.0%
MCCS		0.02	[-0.02; 0.05]	52.3%	52.3%
MESA		-0.09	[-0.29; 0.10]	1.7%	1.7%
NICOLA		0.01	[-0.14; 0.15]	2.9%	2.9%
RS		0.02	[-0.14; 0.18]	2.3%	2.3%
TILDA		0.02	[-0.14; 0.18]	2.3%	2.3%
Fixed effect model	\$	0.01	[-0.01; 0.04]	100.0%	
Random effect mode $I^2 = 0.0\%, \tau^2 = 0$	-0.4 -0.2 0 0.2 0.4	0.01	[-0.01; 0.03]	-	100.0%

lazard ratio [log]

Study	Indirect Effect by DNAmGrimAA	log(HR)	95% CI	Weight (fixed)	Weight (random)
EPIC-IT	<u> </u>	-0.03	[-0.11; 0.05]	15.2%	19.3%
ESTHER		0.01	[-0.06; 0.08]	19.4%	22.6%
KORA		0.09	[-0.06; 0.24]	4.2%	6.9%
MCCS	÷	0.02	[-0.02; 0.06]	53.1%	37.2%
MESA	+	-0.11	[-0.36; 0.14]	1.5%	2.6%
NICOLA		0.22	[-0.02; 0.46]	1.6%	2.8%
RS	- <u>-</u>	0.14	[-0.05; 0.33]	2.5%	4.3%
TILDA		0.14	[-0.05; 0.33]	2.5%	4.3%
Fixed effect model	¢	0.02	[-0.01; 0.05]	100.0%	
Random effect mode		0.02	[-0.03; 0.08]		100.0%
$I^2 = 22.7\%, \tau^2 = 0.0008$	-0.4 -0.2 0 0.2 0.4				
	Hazard ratio [log]				

873

874 Supplementary Figure 12. Forest plots of the relative indirect effect by epigenetic ageing 875 biomarkers in women on the relative scale. Hazard ratio (HR) and 95% compatibility 876 intervals (CI) are reported. Weight represents the contribution of each study to the pooled 877 estimates (diamond) as computed by the fixed/random meta-analytic effect model. 878 Heterogeneity across studies is quantified by I^2 and τ^2 .

879 Extended acknowledgements

Cohort	
EPIC-IT	EPIC-Italy was funded by the Associazione Italiana Ricerca contro il Cancro (AIRC).
ESTHER	The ESTHER study was funded by the Baden-Württemberg State Ministry of Science, Research and Arts (Stuttgart, Germany), the German Federal Ministry of Education and Research (Berlin Germany), the German Federal Ministry of Family, Senior Citizens, Women and Youth (Berlin, Germany) and the Saarland State Ministry of Social Affairs, Health, Women and Family (Saarbrücken, Germany). The analyses for this project were supported by a grant from the German Cancer Aid (No. 70113330)
KORA	The KORA study was initiated and financed by the Helmholtz Zentrum München – German Research Center for Environmenta Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria Furthermore, KORA research has been supported within the Munich Center of Health Sciences (MC-Health), Ludwig Maximilians-Universität, as part of LMUinnovativ.
MCCS	Melbourne Collaborative Cohort Study (MCCS) cohor recruitment was funded by VicHealth and Cancer Council Victoria The MCCS was further augmented by Australian National Health and Medical Research Council grants 209057, 396414 and 1074383 and by infrastructure provided by Cancer Counci Victoria. Cases and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database.
MESA	 MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I N01-HC-95159, 75N92020D00005, N01-HC-95160 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC 95162, 75N92020D00006, N01-HC-95163, 75N92020D00004 N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC 95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1 TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881 and DK063491. The MESA Epigenomics & Transcriptomics Studies were funded by NIH grants 1R01HL101250 1RF1AG054474, R01HL126477, R01DK101921, and R01HL135009. Analysis was partially supported by R01HL141292. This manuscript has been reviewed by MESA for scientific conten and consistency of data interpretation with previous MESA publications.
NICOLA	publications.We are grateful to all the participants of the NICOLA Study, and the whole NICOLA team, which includes nursing staff, research scientists, clerical staff, computer and laboratory technicians managers and receptionists. The Atlantic Philanthropies, the Economic and Social Research Council, the UKCRC Centre o Excellence for Public Health Northern Ireland, the Centre for

	Ageing Research and Development in Ireland, the Office of the First Minister and Deputy First Minister, the Health and Social Care Research and Development Division of the Public Health Agency, the Wellcome Trust/Wolfson Foundation and Queen's University Belfast provide core financial support for NICOLA. The authors alone are responsible for the interpretation of the data and any views or opinions presented are solely those of the authors and do not necessarily represent those of the NICOLA Study team.
RS	The Rotterdam Study (RS) is supported by grants from the Municipality of Rotterdam, the NESTOR program for research in
	the elderly (Ministry of Health and Ministry of Education), the
	Netherlands Prevention Fund, the Netherlands Organization for
	scientific research (NWO), the Netherlands Heart Foundation and
	the Rotterdam Medical Research Foundation (ROMERES).
TILDA	Funding for the TILDA project was supported by the Irish
	Government, the Atlantic Philanthropies, and Irish Life plc.

882 Ethical oversight

Cohort name	Ethical Review Board / Institutional Review Board	Decision	
EPIC Italy	Ethical review board of the International Agency for Research on Cancer (IARC)	Approved	
ESTHER	Ethics committees of the University of Heidelberg and of the Medical Association of Saarland	Approved	
MCCS	The Cancer Council Victoria's Human Research Ethics Committee	Approved	
KORA	The Bavarian Chamber of Physicians Ethics Board	Approved	
MESA	Institutional review boards (IRB) at each participating centre and Johns Hopkins School of Medicine IRB	Approved	
NICOLA	the School of Medicine, Dentistry and Biomedical Sciences Ethics Committee, Queen's University Belfast	Approved	
Rotterdam Study	Medical ethics committee of the Erasmus University Medical Centre, Rotterdam	Approved	
TILDA	Faculty of Health Sciences Research Ethics Committee in Trinity College, Dublin	Approved	
Each study was performed in accordance with the Declaration of Helsinki, including written informed consent from all participants.			

883

895 References

- 896 Aryee, M. J., A. E. Jaffe, H. Corrada-Bravo, C. Ladd-Acosta, A. P. Feinberg, K. D. Hansen & R. A. Irizarry 897 (2014) Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium 898 DNA methylation microarrays. *Bioinformatics*, 30, 1363-9.
- 899 Baglietto, L., E. Ponzi, P. Haycock, A. Hodge, M. Bianca Assumma, C. H. Jung, J. Chung, F. Fasanelli, F. 900 Guida, G. Campanella, M. Chadeau-Hyam, K. Grankvist, M. Johansson, U. Ala, P. Provero, E. 901 M. Wong, J. Joo, D. R. English, N. Kazmi, E. Lund, C. Faltus, R. Kaaks, A. Risch, M. Barrdahl, T. 902 M. Sandanger, M. C. Southey, G. G. Giles, P. Vineis, S. Polidoro, C. L. Relton & G. Severi (2017)
- 903 DNA methylation changes measured in pre-diagnostic peripheral blood samples are 904 associated with smoking and lung cancer risk. Int J Cancer, 140, 50-61.
- 905 Burns, F, G. Carney, S. Cruise, P. Devine, A. Devlin, M. Donnelly, D. French, F. Kee, L. Montgomery, D. 906 O'Reilly, A. Scott & M. Tully. 2017. Early key findings from a study of older people in Northern 907
 - Ireland. The NICOLA Study. Belfast: Queen's University, Belfast.
- 908 Campanella, G., S. Polidoro, C. Di Gaetano, G. Fiorito, S. Guarrera, V. Krogh, D. Palli, S. Panico, C. 909 Sacerdote, R. Tumino, P. Elliott, G. Matullo, M. Chadeau-Hyam & P. Vineis (2015) Epigenetic 910 signatures of internal migration in Italy. Int J Epidemiol, 44, 1442-1449.
- 911 Du, P., W. A. Kibbe & S. M. Lin (2008) lumi: a pipeline for processing Illumina microarray. 912 *Bioinformatics*, 24, 1547-8.
- 913 Dugué, P. A., J. K. Bassett, J. E. Joo, L. Baglietto, C. H. Jung, E. M. Wong, G. Fiorito, D. Schmidt, E. 914 Makalic, S. Li, M. Moreno-Betancur, D. D. Buchanan, P. Vineis, D. R. English, J. L. Hopper, G. 915 Severi, M. C. Southey, G. G. Giles & R. L. Milne (2018) Association of DNA Methylation-Based 916 Biological Age With Health Risk Factors and Overall and Cause-Specific Mortality. Am J 917 Epidemiol, 187, 529-538.
- 918 Dugué, P. A., M. T. Brinkman, R. L. Milne, E. M. Wong, L. M. FitzGerald, J. K. Bassett, J. E. Joo, C. H. 919 Jung, E. Makalic, D. F. Schmidt, D. J. Park, J. Chung, A. D. Ta, D. M. Bolton, A. Lonie, A. 920 Longano, J. L. Hopper, G. Severi, R. Saffery, D. R. English, M. C. Southey & G. G. Giles (2016) 921 Genome-wide measures of DNA methylation in peripheral blood and the risk of urothelial 922 cell carcinoma: a prospective nested case-control study. Br J Cancer, 115, 664-73.
- 923 Galobardes, B., J. Lynch & G. D. Smith (2007) Measuring socioeconomic position in health research. 924 Br Med Bull, 81-82, 21-37.
- 925 Guolo, A. & C. Varin (2017) Random-effects meta-analysis: the number of studies matters. Stat 926 Methods Med Res, 26, 1500-1518.
- 927 Hartung, J. & G. Knapp (2001) On tests of the overall treatment effect in meta-analysis with normally 928 distributed responses. Stat Med, 20, 1771-82.
- 929 Holle, R., M. Happich, H. Löwel, H. E. Wichmann & M. K. S. Group (2005) KORA--a research platform 930 for population based health research. Gesundheitswesen, 67 Suppl 1, S19-25.
- 931 Houseman, E. A., W. P. Accomando, D. C. Koestler, B. C. Christensen, C. J. Marsit, H. H. Nelson, J. K. 932 Wiencke & K. T. Kelsey (2012) DNA methylation arrays as surrogate measures of cell mixture 933 distribution. BMC Bioinformatics, 13, 86.
- 934 Leek, J. T., W. E. Johnson, H. S. Parker, A. E. Jaffe & J. D. Storey (2012) The sva package for removing 935 batch effects and other unwanted variation in high-throughput experiments. Bioinformatics, 936 28,882-3.
- 937 Lehne, B., A. W. Drong, M. Loh, W. Zhang, W. R. Scott, S. T. Tan, U. Afzal, J. Scott, M. R. Jarvelin, P. 938 Elliott, M. I. McCarthy, J. S. Kooner & J. C. Chambers (2015) A coherent approach for analysis 939 of the Illumina HumanMethylation450 BeadChip improves data quality and performance in 940 epigenome-wide association studies. Genome Biol, 16, 37.
- 941 Liu, Y., J. Ding, L. M. Reynolds, K. Lohman, T. C. Register, A. De La Fuente, T. D. Howard, G. A. 942 Hawkins, W. Cui, J. Morris, S. G. Smith, R. G. Barr, J. D. Kaufman, G. L. Burke, W. Post, S. Shea, 943 C. E. McCall, D. Siscovick, D. R. Jacobs, R. P. Tracy, D. M. Herrington & I. Hoeschele (2013) 944 Methylomics of gene expression in human monocytes. Hum Mol Genet, 22, 5065-74.

- Martinussen, T. & T. H. Sheike. 2006. *Dynamic regression models for survival data*. New York:
 Springer.
- McEwen, L. M., M. J. Jones, D. T. S. Lin, R. D. Edgar, L. T. Husquin, J. L. MacIsaac, K. E. Ramadori, A. M.
 Morin, C. F. Rider, C. Carlsten, L. Quintana-Murci, S. Horvath & M. S. Kobor (2018) Systematic
 evaluation of DNA methylation age estimation with common preprocessing methods and the
 Infinium MethylationEPIC BeadChip array. *Clin Epigenetics*, 10, 123.
- McKeague, I. W. & P. D. Sasieni (1994) A partly parametric additive risk model. *Biometrika*, 81, 501514.
- Milne, R. L., A. S. Fletcher, R. J. MacInnis, A. M. Hodge, A. H. Hopkins, J. K. Bassett, F. J. Bruinsma, B.
 M. Lynch, P. A. Dugué, H. Jayasekara, M. T. Brinkman, L. V. Popowski, L. Baglietto, G. Severi,
 K. O'Dea, J. L. Hopper, M. C. Southey, D. R. English & G. G. Giles (2017) Cohort Profile: The
 Melbourne Collaborative Cohort Study (Health 2020). *Int J Epidemiol*, 46, 1757-1757i.
- 957 Nguyen, Q. C., T. L. Osypuk, N. M. Schmidt, M. M. Glymour & E. J. Tchetgen Tchetgen (2015) Practical
 958 guidance for conducting mediation analysis with multiple mediators using inverse odds ratio
 959 weighting. *Am J Epidemiol*, 181, 349-56.
- Palli, D., F. Berrino, P. Vineis, R. Tumino, S. Panico, G. Masala, C. Saieva, S. Salvini, M. Ceroti, V. Pala,
 S. Sieri, G. Frasca, M. C. Giurdanella, C. Sacerdote, L. Fiorini, E. Celentano, R. Galasso, A.
 Decarli, V. Krogh & EPIC-Italy (2003) A molecular epidemiology project on diet and cancer:
 the EPIC-Italy Prospective Study. Design and baseline characteristics of participants. *Tumori*,
 964 89, 586-93.
- Pidsley, R., C. C. Y Wong, M. Volta, K. Lunnon, J. Mill & L. C. Schalkwyk (2013) A data-driven approach
 to preprocessing Illumina 450K methylation array data. *BMC Genomics*, 14, 293.
- Raum, E., D. Rothenbacher, M. Löw, C. Stegmaier, H. Ziegler & H. Brenner (2007) Changes of
 cardiovascular risk factors and their implications in subsequent birth cohorts of older adults
 in Germany: a life course approach. *Eur J Cardiovasc Prev Rehabil*, 14, 809-14.
- Riboli, E. (2001) The European Prospective Investigation into Cancer and Nutrition (EPIC): plans and
 progress. *J Nutr*, 131, 170S-175S.
- 972 Schwarzer, G., J. Carpenter & G. Rücker. 2015. *Meta-analysis with R*. Springer Publishing
 973 International.
- 974 Severi, G., M. C. Southey, D. R. English, C. H. Jung, A. Lonie, C. McLean, H. Tsimiklis, J. L. Hopper, G. G.
 975 Giles & L. Baglietto (2014) Epigenome-wide methylation in DNA from peripheral blood as a
 976 marker of risk for breast cancer. *Breast Cancer Res Treat*, 148, 665-73.
- Smyth, G. K. 2005. limma: Linear Models for Microarray Data. In *Bioinformatics and Computational Biology Solutions Using R and Bioconductor*, eds. R. Gentleman, V. J. Carey, W. Huber, R. A.
 Irizarry & S. Dudoit, 397-420. New York, NY: Springer New York.
- Steen, J., T. Loeys, B. Moerkerke & S. Vansteelandt (2017) Flexible Mediation Analysis With Multiple
 Mediators. *Am J Epidemiol*, 186, 184-193.
- Stensrud, M. J. & M. A. Hernán (2020) Why Test for Proportional Hazards? *JAMA*, 323, 1401-1402.
- Tchetgen, E. J. & I. Shpitser (2012) Semiparametric Theory for Causal Mediation Analysis: efficiency
 bounds, multiple robustness, and sensitivity analysis. *Ann Stat*, 40, 1816-1845.
- Tchetgen Tchetgen, E. J. (2013) Inverse odds ratio-weighted estimation for causal mediation analysis.
 Stat Med, 32, 4567-80.
- 987 Teschendorff, A. E., F. Marabita, M. Lechner, T. Bartlett, J. Tegner, D. Gomez-Cabrero & S. Beck
 988 (2013) A beta-mixture quantile normalization method for correcting probe design bias in
 989 Illumina Infinium 450 k DNA methylation data. *Bioinformatics*, 29, 189-96.
- Valeri, L., X. Lin & T. J. VanderWeele (2014) Mediation analysis when a continuous mediator is
 measured with error and the outcome follows a generalized linear model. *Stat Med*, 33,
 4875-90.
- 993 VanderWeele, T. J. 2015. *Explanation in Causal Inference: Methods for Mediation and Interaction*.
 994 New York: Oxford University Press.

- 995 VanderWeele, T. J., L. Valeri & E. L. Ogburn (2012) The role of measurement error and
 996 misclassification in mediation analysis: mediation and measurement error. *Epidemiology*, 23,
 997 561-4.
- VanderWeele, T. J. & S. Vansteelandt (2014) Mediation Analysis with Multiple Mediators. *Epidemiol Methods*, 2, 95-115.
- Whelan, B. J. & G. M. Savva (2013) Design and methodology of the Irish Longitudinal Study on
 Ageing. J Am Geriatr Soc, 61 Suppl 2, S265-8.
- Wiksten, A., G. Rücker & G. Schwarzer (2016) Hartung-Knapp method is not always conservative
 compared with fixed-effect meta-analysis. *Stat Med*, 35, 2503-15.
- Wilson, R., S. Wahl, L. Pfeiffer, C. K. Ward-Caviness, S. Kunze, A. Kretschmer, E. Reischl, A. Peters, C.
 Gieger & M. Waldenberger (2017) The dynamics of smoking-related disturbed methylation: a
 two time-point study of methylation change in smokers, non-smokers and former smokers.
 BMC Genomics, 18, 805.
- Wong Doo, N., E. Makalic, J. E. Joo, C. M. Vajdic, D. F. Schmidt, E. M. Wong, C. H. Jung, G. Severi, D. J.
 Park, J. Chung, L. Baglietto, H. M. Prince, J. F. Seymour, C. Tam, J. L. Hopper, D. R. English, R.
 L. Milne, S. J. Harrison, M. C. Southey & G. G. Giles (2016) Global measures of peripheral
 blood-derived DNA methylation as a risk factor in the development of mature B-cell
 neoplasms. *Epigenomics*, *8*, 55-66.
- Zeilinger, S., B. Kühnel, N. Klopp, H. Baurecht, A. Kleinschmidt, C. Gieger, S. Weidinger, E. Lattka, J.
 Adamski, A. Peters, K. Strauch, M. Waldenberger & T. Illig (2013) Tobacco smoking leads to
 extensive genome-wide changes in DNA methylation. *PLoS One*, 8, e63812.
- Zhang, Y., B. Schöttker, I. Florath, C. Stock, K. Butterbach, B. Holleczek, U. Mons & H. Brenner (2016)
 Smoking-Associated DNA Methylation Biomarkers and Their Predictive Value for All-Cause
 and Cardiovascular Mortality. *Environ Health Perspect*, 124, 67-74.
- Zhang, Y., R. Wilson, J. Heiss, L. P. Breitling, K. U. Saum, B. Schöttker, B. Holleczek, M. Waldenberger,
 A. Peters & H. Brenner (2017) DNA methylation signatures in peripheral blood strongly
 predict all-cause mortality. *Nat Commun*, 8, 14617.
- 1022